Analysis of Ptp10D and Ptp4E during ageing and in Parkinson Disease models in Drosophila melanogaster by Zadabedini Masouleh, Tahereh
i 
 
Analysis of Ptp10D and Ptp4E during ageing and in 
Parkinson Disease models in Drosophila melanogaster 
 
By 
   Tahereh Zadabedini Masouleh, B.Sc. 
 
 
 
A thesis submitted to the 
School of Graduate Studies 
In partial fulfillment of the requirement for the degree of 
Master of Science 
 
Department of Biology 
Memorial University of Newfoundland 
 
2019 
 
 
 
 
St. John’s                                                                           Newfoundland and Labrador  
 
 
 
 
 
ii 
 
Abstract 
 
Parkinson Disease (PD) is an age-dependent neurological disease that diminishes 
locomotory abilities. PD is the second most common neurodegenerative disease, after 
Alzheimer Disease (AD), with a lifetime risk of approximately one in 40 in human. The 
symptoms of PD include resting tremors, rigidity, and bradykinesia and are caused by a 
loss of dopaminergic neurons in the substantia nigra of the midbrain. Based upon a 
recent study, a group of novel candidate genes was discovered with the potential to 
influence PD etiology. Protein tyrosine phosphatase receptor type H (PTPRH) is one of 
the candidate genes with an established role in controlling mitochondrial morphology, 
which is a very important organelle in the development of PD. Importantly, PTPRH 
protein has roles in many cellular processes, including cell growth, the mitotic cycle, 
and differentiation.  
In the current study, Ptp10D and Ptp4E were identified as potential D. 
melanogaster homologues of PTPRH that are apparently the products of a gene 
duplication event. I show that PTPRH homologues in D. melanogaster have been 
conserved throughout evolution in vertebrates and invertebrates possessing a number of 
distinct conserved functional domains. Biometric, longevity, and climbing assays were 
performed to determine if altered expression of these genes could influence 
neurodevelopment, longevity and quality of life and/or produce novel models of PD. 
The individual inhibition of either Ptp10D or Ptp4E decreases the lifespan and 
locomotor ability over time. As well, directed loss of function has deleterious effects on 
neurodevelopment when inhibited in the compound eye. Interestingly, similar results 
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were observed with regards to longevity, climbing over time, and eye biometric analyses 
when Ptp4E was overexpressed. In conclusion, altered expression of homologues of 
PTPRH in D. melanogaster, either ectopic overexpression or inhibition via RNAi, 
influences overall health and ageing to result in new potential models of PD. 
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Introduction 
Purpose 
Parkinson Disease (PD) is the most common neurodegenerative movement 
disease. As such, it is vital to understand the underlying mechanisms and pathways 
responsible for PD in order to treat and/or prevent it. The aim of this research is to 
characterize the potential relationship of the Ptp10D and/or Ptp4E genes and Parkinson 
disease through the examination of the consequences of inhibition and overexpression 
in the model organism Drosophila melanogaster. 
 
Parkinson Disease 
Parkinson Disease (PD) is a neurological disease in which age-dependent loss of 
locomotion abilities is the best-known feature. PD was first medically defined by Dr. 
James Parkinson in 1817 as a neurological disorder (Parkinson, 1817). In 1872, 
observations of patients with resting tremor led to classifying PD as a distinct 
neurological disorder which had been formerly categorized with other tremorous 
disorders such as multiple sclerosis based on early symptoms (Charcot, 1872). PD is 
characterized by degeneration of dopaminergic neurons in the zona compacta of the 
substantia nigra in the midbrain (Fearnley & Lees, 1991). Often the loss of 
dopaminergic neurons is accompanied by the presence of α-synuclein-enriched 
aggregation, which is a key component of Lewy bodies, abnormal aggregates of protein 
inside nerve cells (Goedert, 2001). These eosinophilic inclusions are believed to be a 
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neuropathological marker of PD (Savitt, Dawson, & Dawson, 2006). Although a great 
deal of effort has been devoted to discover the cause(s) of the disease, there is much left 
to discover. 
There are motor and non-motor symptoms associated with this progressive 
neurodegenerative movement disease. Slowness of movement, rigidity, resting tremor, 
and postural disability are the conspicuous locomotion and motor control-related 
characteristics (Shahed & Jankovic, 2007). The presence of at least two of the principal 
symptoms is a requirement for diagnosis of the disease (Nussbaum & Polymeropoulos, 
1997). In spite of the emphasis on motor symptoms, non-motor symptoms are important 
when it comes to the quality of life and life expectancy (Chaudhuri, Healy, & Schapira, 
2006). Non-motor symptoms, including depression, anxiety, sleeping disorders, pain, 
and sexual dysfunction are common and occur across all stages of PD (Chaudhuri & 
Schapira, 2009). There is no curative treatment for this chronic disease, but some 
treatments are available to control some of the symptoms. 
PD is the second most common neurodegenerative disease, after Alzheimer 
Disease (AD), with the lifetime risk of one in 40 (Schapira, 1995). The incidence rates 
of PD is from eight to 18 per 100,000 person-years (De Lau & Breteler, 2006). There is 
a sharp increase in the incidence after age 60 years, whereas the onset of the disease 
before age 50 years is rare (Erkkinen, Kim, & Geschwind, 2018). The average 
standardized incidence rate of PD in the US and other developed countries have been 
approximated 14 per 100,000 person-year. When studies were confined to cases over 
the age of 65, the average incidence rate was increased to 160 per 100,000 person-year, 
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to strongly suggest that PD is an age-dependent disease (Hirtz et al., 2007). An 
epidemiologic study was conducted of cases diagnosed with idiopathic PD Parkinson's 
disease from northern California has shown that the age-adjusted incidence rate for men 
was 19 per 100,000 and 9.9 per 100,000 person-years for women (male: female ratio= 
1.9) (Van Den Eeden et al., 2003). Based on epidemiological research, age, race, and 
gender are the most important risk factors. 
Based on several studies, the rate of incidence of PD in men is higher than 
women with the range of male to female ratios of 0.9 to 2.6 (De Lau & Breteler, 2006). 
A remarkably higher incidence rate of PD amongst men can be explained by 
neuroprotective effects of estrogens and recessive susceptibility of PD genes on the X 
chromosome (Wooten, Currie, Bovbjerg, Lee, & Patrie, 2004). The incidence of PD, 
regardless of age and gender, is the highest among the Hispanics in Northern California 
population. Non-Hispanic Caucasian Asians, and African Americans had lower rates, 
respectively (Van Den Eeden et al., 2003). This research suggests that the incidence of 
PD differs by ethnicity, which supports the role of hereditary in this disease. 
For many years, no correlation between PD and inheritance was recognized and, 
therefore, environmental factors were considered as the only cause of the disease. 
However, in the past number of decades, the identification of genes for monogenic forms 
of the disease has led to a growing understanding of the molecular mechanisms of PD 
(Gasser, 2009). Approximately 10 to 15% of patients have a positive family history of 
PD in accordance with a Mendelian (autosomal dominant or autosomal recessive) 
inheritance (De Lau & Breteler, 2006). There is no specific clinical symptom which 
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distinguishes the familial form of the disease from sporadic except age: many patients 
with the familial form are younger at disease onset (Gasser, 2007). Although the familial 
form of PD comprises a small portion of cases the identification of associated genes and 
their functions has led to a deeper understanding of the pathogenesis of PD. 
 
Genetics aspects of PD 
William Gowers, a British neurologist, was the first who suggested that there 
might be hereditary factors by observing a suffering case in the relatives of a patient 
with PD (summarized in Schapira, 1995). To date, at least 24 chromosomal regions or 
loci (Table 1) have been linked to PD (Del Rey et al., 2018). However, only 19 distinct 
genes of 24 loci have been identified by performing linkage analysis and genome 
sequencing (Deng, Wang, & Jankovic, 2018). In addition, a genome-wide association 
study (GWAS) has shown over 20 common variants with small effect size on PD cases 
(Hernandez, Reed, & Singleton, 2016). Nine of the established PD genes are autosomal 
recessive and the rest are autosomal dominant genes. 
In the late 20th century, the first PD gene (SNCA) was identified by linkage study 
in the familial form of PD (FPD) with autosomal dominant inheritance (Polymeropoulos 
et al., 1997). The SNCA gene encodes the α-synuclein protein in which missense 
mutations cause the accumulation of protein inclusions within the inner membrane of 
mitochondria and subsequent cell death (Liu et al., 2009). Afterward, mutations in 
parkin/PARK2 were recognized in Japanese families with the young-onset of symptoms 
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(Kitada et al., 1998). In addition, a mutation in ubiquitin c-terminal hydrolase 1 (Uchl-
1)/PARK5 (Leroy et al., 1998) and Leucine-rich repeat kinase 2 (LRRK2)/Park8 (Paisán-
Ruı́z et al., 2004) lead to the autosomal dominant form of PD. Furthermore, mutations 
in five more genes with a small sample size in FPD, including HTRA2, vascular sorting 
protein 35 (vsp35), EIF4GI, DNAJC13, and CHCHD2, have an autosomal dominant 
inheritance (Karimi-Moghadam, Charsouei, Bell, & Jabalameli, 2018). Many of PD-
linked genes encode proteins which directly or indirectly have a role in mitochondrial 
homeostasis or mitophagy (Ryan, Hoek, Fon, & Wade-Martins, 2015). Mutation in three 
main genes including PARK6 (PINK1), PARK2 (parkin), and PARK7 (DJ-1) which play 
an important part in mitochondrial homeostasis leads to autosomal recessive or loss of 
function forms of PD (Bekris, Mata, & Zabetian, 2010). The list of PD-related genes is 
getting longer by the day (Table 1; based on (Del Rey et al., 2018; Zhang, Chen, Zhang, 
Wang, & Fernandez-Funez, 2018)), which highlights the role of genetics in this disease. 
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Table 1: PD-related genes and risk factors loci 
 
Locus  Gene name Location Inheritance a Onset b Function 
PARK1/4 SNCA 4q21.3-q22 AD EO Synaptic protein vesicles 
dynamics 
PARK2 PARKIN 6q25.2-q27 AR EO Mitophagy 
PARK3 Unknown 2p13 AD LO Unknown 
PARK5 UCHL1 4p13 AD LO Proteasome 
PARK6 PINK1 1p36.12 AR EO Mitophagy 
PARK7 DJ-1 1p36.23 AR EO Mitophagy 
PARK8 LRRK2 12q12 AD LO Autophagy 
PARK9 ATP13A2 1p36 AR EO Lysosome 
PARK10 Unknown 1p32 Risk factor LO Unknown 
PARK11 GIGYF2 2q36-7 AD LO IGFs signalling 
PARK12 Unknown Xq21-q22 X-linked  LO Unknown 
PARK13 HTRA2 2p13.1 AD LO/EO Mitophagy 
PARK14 PLA2G6 22q13.1 AR EO Lipid metabolism 
PARK15 FBXO7 22q12.3 AR EO Mitophagy 
PARK16 Unknown 1q32 Unknown LO Unknown 
PARK17 VPS35 16q12 AD LO Endosomes 
PARK18 EIF4G1 3q27.1 AD LO Protein translation 
PARK19 DNAJC6 1p31.3 AR EO Endosomes 
PARK20 SYNJ1 21q22.11 AR EO Endosomes 
PARK21 DNAJC13 3q22.1 AD LO Endosomes 
PARK22 CHCHD2 7p11.2 AD LO/EO Apoptosis 
PARK23 VPS13C 15q22.2 AR EO Mitophagy 
     -- GBA 1q22 AD LO Lysosomes 
     -- MAPT 17q21.31 Sporadic risk 
factor 
Unkno
wn 
Microtubules 
a AD is autosomal dominant, AR is autosomal recessive 
b EO is early-onset, LO is late-onset  
 
7 
 
Role of mitochondria in PD 
Mitochondria, with their double-membrane structure, are crucial organelles that 
generate energy in cells in the form of Adenosine Triphosphate (ATP). For neuron-rich 
tissues like brain, mitochondria are of great importance due to the inability of these 
tissues to derive sufficient energy by glycolysis (Karbowski & Neutzner, 2012). There 
are various cellular mechanisms that help to maintain mitochondrial function through 
which either impaired harmful organelles are broken down or biogenesis of new 
mitochondria occurs. Balanced fission and fusion in mitochondria is a key aspect of their 
functionality in terms of protection of mitochondrial DNA, mitochondrial turnover, and 
bioenergetics function (Bose & Beal, 2016). Complex I, located in the inner membrane 
of mitochondria, plays a vital role in the oxidative phosphorylation system. Thus, 
damage to this complex leads to the dysfunction of mitochondria and subsequent 
dopaminergic (DA) neuron death (Schapira, 2007). Intact function of mitochondria is 
crucial to prevent the death of DA neurons and subsequent higher risk of PD.  
Neurotoxin exposure, including 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine 
(MPTP) and rotenone, can lead to mitochondrial damage by affecting complex I activity 
and therefore they are considered as environmental factors related to PD (Philippens, 
2018). Moreover, the rate of mitochondrial DNA mutation is higher in PD patients 
compared to the non-PD population with the same age (Wang, Abraham, Gao, & Yang, 
2016). As a result of mitochondrial dysfunction, reactive oxygen species (ROS) are 
generated which leads to oxidative stress in the cell (Trushina & McMurray, 2007). 
Activation of cell death signalling pathways via the increase of ROS and oxidative stress 
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has been reported (Moon & Paek, 2015). Degeneration of DA neurons is catalyzed by 
oxidative stress and as such mitochondria are crucial in PD. 
Most of the PD-linked genes encode proteins which directly or indirectly have a 
role in mitochondrial homeostasis. In fact, mutant forms of PD genes increase 
mitochondrial damage and impair clearance of dysfunctional mitochondria that cause 
cellular stress (Aryal & Lee, 2019). The α-synuclein protein, encoded by SNCA, is 
situated in association with the inner membrane of mitochondria by its mitochondrial 
specific signal in the N-terminal 32 amino acids. The process of α-synuclein aggregation 
in the mitochondrial membrane in dopaminergic neurons leads to complex I dysfunction 
and subsequent higher rate of ROS production (Devi, Raghavendran, Prabhu, Avadhani, 
& Anandatheerthavarada, 2008). As a result, mitochondrial membrane potential may 
become disrupted and this may eventually lead to cell death (Devoto & Falzone, 2017). 
PINK1 and Parkin are proteins with distinct roles in mitochondrial maintenance (Wang 
et al., 2016). PINK1 is localized in mitochondria and mutations in the gene that encodes 
this protein result in a rare form of autosomal recessive PD by deactivating NADH and 
disrupting the electron transport chain in mitochondria (Scialò et al., 2016). Moreover, 
the loss of Parkin causes mitochondrial degradation and increases cellular susceptibility 
to oxidative stress (Aryal & Lee, 2019). Mutations in Parkin have been shown to result 
in early onset juvenile autosomal recessive PD which is associated with accumulation 
of its substrates (Rakovic et al., 2011). The PINK1/Parkin pathway is essential for 
mitochondrial function. Null mutants of both protein encoding genes in Drosophila 
demonstrate impaired mitochondrial turnover and mitophagy (Vincow et al., 2013). Due 
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to the importance of mitochondria in PD etiology, many PD studies evaluate parameters 
which are related to mitochondrial morphology. 
Given the role of Fbxo7 protein in inducing mitophagy via direct interactions 
with Parkin, it is marked as a PD gene involved in mitochondrial maintenance (Wang et 
al., 2016). Mutation in this gene leads to autosomal recessive PD at the early onset which 
highlights the effect of mitochondrial dysfunction and oxidative stress in PD 
pathogenesis.  
 
Genes of interest 
Protein tyrosine phosphatase receptor type H, PTPRH is a protein-coding gene. 
PTPRH, also called stomach cancer-associated protein-tyrosine phosphatase-1 (SAP-1) 
was first identified in human stomach cells (Matozaki, T. et al., 1994). This protein is a 
member of the protein tyrosine phosphatase (PTP) family. The presence of structurally 
conserved domain, which is called PTP, determines the membership (Andersen et al., 
2001). PTPs remove phosphate groups from tyrosine residues in proteins and therefore 
are considered as part of a signal transduction pathway set of enzymes. The level of 
tyrosine phosphorylation in cellular proteins is controlled by PTPs and protein tyrosine 
kinases (PTKs), as PTKs phosphorylate proteins on tyrosine residues (Hunter, 1998). 
These signalling molecules have a role in plenty of cellular processes, including cell 
growth, the mitotic cycle, and differentiation (Moura & Conde, 2019). Each PTP 
contains one or two catalytic sites with a conserved amino acid sequence 
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(I/V)HCXAGXXR(S/T) G (X: any amino acid). In this sequence, cysteine has a crucial 
role in catalyzing dephosphorylation (Baig, Ahmad, Rabbani, & Choi, 2018). PTPs and 
PTKs together regulate the phosphorylation level of many signalling proteins and 
therefore have important roles in signalling pathways. 
PTPs are categorized into three distinct groups: the classical PTPs, dual-
specificity PTPs, and the low molecular weight PTPs. The classical PTPs are then 
divided into two subgroups named transmembrane receptor and non-receptor PTPs. 
Most transmembrane receptor-like PTPs (RPTPs) are made up of one to two cytoplasmic 
PTP catalytic domains, a membrane proximal and distal domain (D1and D2), and single 
transmembrane segment as well as an extracellular domain (Du & Grandis, 2015). 
PTPRH, the focus of this study, has one PTP conserved domain in the cytoplasm, a 
single transmembrane region, as well as an extracellular region in which there are eight 
fibronectin type III-like (FN3) structure repeats and multiple N-glycosylation sites 
(Hendriks, Elson, Harroch, & Stoker, 2008). The FN III repeats in PTPRH unlike other 
RPTP induce protein dimerization and thereby control the enzyme’s activity (Wälchli, 
Espanel, & Van Huijsduijnen, 2005). Despite all of the studies that have been done on 
RPTPs with two catalytic domains, RPTPs with a single domain remained relatively 
known. 
In humans, the PTPRH gene is located on the long arm of chromosome 19 in the 
q13.42 region. In studies on normal tissue, it was shown that PTPRH is widely expressed 
in brain, liver, and then at a lower level in heart and stomach (Matozaki, Takashi & 
Kasuga, 1996). Moreover, high expression of PTPRH was detected in pancreatic and 
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colorectal cancer cell lines (CRC). Therefore, it was considered as an oncogenic factor 
(Seo et al., 1997). However, it has been shown that there is a lower expression of PTPRH 
in an advanced stage of colorectal cancer and human hepatocellular cancer (Nagano et 
al., 2003). In one study, the mRNA expression in colorectal adenomas, normal mucosa, 
and CRC cells was compared by microarrays and the analysis showed that the PTPRH 
expression was reduced the most in CRC cells, which supports the possible tumor 
suppressor role of PTPRH (Skrzypczak et al., 2010). Later, another study measured the 
mRNA and protein level in healthy adenoma and mucosa, as well as CRC samples. 
Immunohistochemical staining of the tumor and normal mucosa samples was conducted 
to confirm the first set of results through which it has been proven that the protein 
expression was decreased in CRC samples. These results demonstrate that PTPRH is 
downregulated in the colorectal tumor (Bujko et al., 2017). Although there are unknown 
aspects concerning the role of PTPRH, it is likely that this protein has a tumor suppressor 
function. 
To understand the distinct function of PTPRH, recognition of its physiological 
substrates is essential. The identification of substrates for this enzyme has been difficult 
due to the transient nature of the binding between PTPRH and its substrates (Matozaki, 
Takashi et al., 2010). In 2001, Noguchi et al. identified p130cas as a potential 
physiological substrate for PTPRH by the substrate-trapping method. This protein is a 
focal adhesion-associated phosphotyrosyl protein which is involved in various cellular 
processes including migration, apoptosis, and cell adhesion. It has been observed that 
besides p130cas, PTPRH induces dephosphorylation of focal adhesion kinase and 
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p62dok, which are two other proteins of the integrin-signalling pathway (Noguchi et al., 
2001). P130cas is involved in different cerebellum development stages (Hourani, 
Mendes, Berretta, & Moscato, 2007). Cerebellum is identified as a potential source of 
some of the PD symptoms which explains its possible role in the pathophysiology of PD 
(Wu & Hallett, 2013). Due to the different expression level of p130cas in PD, abnormal 
expression level of p130Cas may associated with PD (Sun, Ye, Zheng, & Yang, 2018). 
Based on the evidence for the potential roles of p30Cas in PD, PTPRH may be acting 
through focal adhesion substrates to influence PD. 
Abundance of PTPRH in brain tissue (Matozaki, T. et al., 1994) and the presence 
of fibronectin type III-like domain in many neural cells suggest that PTPRH has a role 
in the signalling pathway of neural cell-cell adhesion (Noguchi et al., 2001). 
Furthermore, the overexpression of PTPRH in a fibroblast cell line leads to apoptotic 
cell death by at least two cellular mechanisms: inhibiting the survival signalling induced 
by both Akt (protein kinase B) and integrin-linked kinase (ILK) and activating the 
cellular pro-apoptotic pathway (Takada et al., 2002). These findings suggest that PTPRH 
affects signalling pathways regarding cell proliferation, survival, apoptosis, and cell 
motility. 
  Whole exome sequencing (WES) is one of the valuable tools when it comes to 
the identification of new genes that cause the familial form of PD. A large-scale whole 
exome sequencing was performed in 1148 unrelated PD cases in 2017 with the purpose 
of identifying and prioritizing novel PD candidate genes. The analysis focus was on 
genes with homozygous or compound heterozygous loss-of-function (LOF) variants. 
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Therefore, they selected cases with the younger age of PD onset which is related to 
recessive inheritance. The 27 candidate genes, including PTPRH, were found during 
their primary analysis with the confirmation of Sanger sequencing. Based on WES 
results, PTPRH is a compound heterozygote with the functional validation for 
assessment in both approved PD mechanisms: mitochondrial morphology and α-
synuclein-induced neurodegeneration. Then, they examined each candidate gene on the 
expression networks derived from the human substantia nigra to produce a co-
expression pattern with established PD genes. It was found that PTPRH is co-expressed 
with the gene FBXO7 (Jansen et al., 2017). Mutant forms of FBXO7 can lead to protein 
aggregation and subsequent impaired mitochondrial function due to FBXO7 interaction 
with PINK1 and parkin (Burchell et al., 2013). By use of enrichment analysis, it has 
been observed that PTPRH is expressed in an oligodendrocyte markers-enriched 
network (Jansen et al., 2017). Higher expression of PTPRH in this network suggests that 
this protein has a potential function in the substantia nigra of the midbrain which is 
associated with PD. 
As it was noted before, mitochondrial dysfunction plays an important role in PD-
causative mechanisms. After the identification of a group of novel candidate PD genes, 
Jansen and colleagues ran the second phase of their experiment to prioritize the genes 
based on their possible related function in PD. Due to this, they chose 13 candidate genes 
to see if the knockdown of each gene shows a substantial impact on at least one of the 
three parameters for quantification of mitochondrial morphology: mitochondrial 
number, axial length ratio, and roundness. Knockdown of PTPRH in neuroblastoma cell 
14 
 
lines leads to an increase in axial length ratio which demonstrates its role in 
mitochondrial morphology (Jansen et al., 2017). It is interesting to observe that based 
on the Human Protein Atlas (HPA) program, which tries to map all human proteins in 
different cells, tissues, and organs, the subcellular location of PTPRH is mitochondria 
(https://www.proteinatlas.org/). This information helps to prove the role of PTPRH in 
mitochondria and its subsequent role in PD formation. 
 
Drosophila melanogaster as a model organism 
The fruit fly Drosophila melanogaster has been chosen for over a century as a 
model organism for genetic studies and it is one of the first organisms with a fully 
sequenced genome. For the first time, D. melanogaster was sequenced in March 2000 
in order to verify the shot-gun sequencing approach (Jennings, 2011). Approximately 
15000 genes have been identified in D. melanogaster which are all carried on only four 
chromosomes and they can be easily observed in the polytene chromosomes of the larval 
salivary gland (St. Johnston, 2002). Thus, a higher density of genes per chromosome 
can be observed compared to humans. 
To enumerate the essential characteristics of D. melanogaster that make this fly 
as an effective model system, the close relationship between the fruit fly and human 
genome should first be considered. To be precise, 75% of human disease genes have a 
homologue in fruit flies, which are easy to manipulate (Pandey & Nichols, 2011). The 
other benefit of D. melanogaster that allows scientists to carry out research easily is its 
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12-day life cycle with a lot of offspring that is easy to keep and grow (Jennings, 2011). 
Short lifespan is another advantage of this organism which is especially beneficial for 
researching on neurodegenerative diseases (Prüßing, et al., 2013). Moreover, the 
presence of external components, including interommatidial bristles, compound eyes, 
and wing veins facilitates the observation of the impacts of various mutations on 
phenotype (St. Johnston, 2002). All these aspects make this organism a convenient 
model to work with in the laboratory condition.  
Modeling human neurodegenerative diseases requires an organism with a 
complex central nervous system (CNS). Although fruit flies possess relatively small 
brains, their nervous system is more complex than that of in C. elegans (Nass & 
Przedborski, 2011). The D. melanogaster CNS consists of a three-lobed brain and a 
ventral nerve cord with bilateral symmetry (Nass & Przedborski, 2011). The larval D. 
melanogaster CNS contains approximately 125,000 neurons which increases up to 
250,000 neurons in the complex adult CNS with millions of connections (Lambrechts, 
Faber, & Sibon, 2018). The ventral nerve cord is made up of ganglia containing motor 
neurons and interneurons, a necessity to manage the body segments that they innervate. 
However, the brain in D. melanogaster contains neurons playing role in memory, 
learning, and sensory processing (Keene & Waddell, 2007). As well, dopaminergic 
neurons which are of great importance in PD studies can be widely seen in the D. 
melanogaster CNS and they have important roles in memory, learning, mating, and 
locomotion control (Nass & Przedborski, 2011). This range of similarities between the 
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D. melanogaster and human nervous systems, in both components and functions, make 
this organism an ideal model for studying neurodegenerative disease, especially PD. 
Drosophila melanogaster has been extensively used to address underlying 
mechanisms in a wide range of neurodegenerative diseases including polyglutamine 
disorder, Alzheimer Disease and Parkinson Disease (Lambrechts et al., 2018). Besides 
the advantages mentioned above, having compound eyes makes this model organism a 
unique tool for the study of human disease associated with the nervous system. The eye 
of D. melanogaster is a highly effective model system to analyze molecular interactions 
and developmental mechanisms of the nervous system (Şahin & Çelik, 2001). This 
anatomical feature provides an easy determination of any phenotypic change (Iyer et al., 
2016). The D. melanogaster eye differentiates from the eye imaginal disc as a first part 
of the adult nervous system (Cagan, 2009). Each eye is made up of 700 to 800 eye units 
known as ommatidia. Ommatidia have a hexagonal shape with the same size and even 
spacing (Figure 1) (Tsachaki & Sprecher, 2012). Eight photoreceptor neurons, four non-
neuronal cone cells and two pigment cells are present in each unit (Baker, Li, Quiquand, 
Ruggiero, & Wang, 2014). The presence of more than 6000 neurons in each eye leads 
to the visibility of any defects in eye development. Likewise, since the eye is a repetitive 
structure, gain or loss of function conditions which disturb eye development can be 
easily recognized in the adult eye as a “rough eye” (Lambrechts et al., 2018). 
Interommatidial bristle, ommatidia number, eye surface area, and size of ommatidia can 
be quantified in the rough eye (Iyer et al., 2016). This feature is beneficial to the study 
of gene functions or the effect of expressing mutant genes. 
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Despite all the advantages that flies offer to researchers, there are some 
drawbacks that should be taken into consideration while choosing this organism as a 
model of the study. One of the main drawbacks of working with flies is that they should 
be maintained in living stocks during the experiment since there is no practical way to 
freeze the stocks (Gonzalez, 2013). Sometimes, the homologue of the desired gene in 
invertebrates such as flies is not functionally and/or structurally relevant to the 
corresponding human protein or the proteins might not be well conserved (Nass & 
Przedborski, 2011). As an example, the LRRK2 protein in humans has an N-terminal 
domain which does not exist in its homologue in invertebrates, which can lead to a 
potential limitation (Marín, 2006). Therefore, taking advantage of D. melanogaster as 
an effective model organism is based on the research question. 
 
Drosophila melanogaster genetic tools 
With the growing role of D. melanogaster in research, greater number of genetic 
tools have been developed. Forward genetic screens and reverse genetics are two ways 
of experimental manipulation employed in order to create D. melanogaster models of 
human disease. With the aid of forward genetic screens, phenotype producing genes can 
be selected in an unbiased manner to be analyzed based on the behavioral or cellular 
phenotypes produced (Jeibmann & Paulus, 2009). This tool allows researchers to 
identify unknown genes in a particular pathway, in which selected mutant genes are 
isolated to be mapped. Furthermore, protein-coding genes that are able to modify the 
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gene expression (suppressors/enhancer) can be detected through modifier screen in 
forward genetic screens.  
Compared to forward genetics, reverse genetics is conducted to identify the 
potential function of a known human disease gene. One of the most instrumental 
manipulation tools which have been applied in reverse genetic is the Gal4/UAS system 
(see Figure 2). For the ectopic expression of a specific gene in tissue and the time-
specific manner in D. melanogaster, the Gal4/UAS system is widely used (Brand & 
Perrimon, 1993). This binary system comprises two distinct transgenic lines: (1) the 
directing or driver line carrying the yeast transcription factor encoding Gal4 transgene, 
derived from Saccharomyces cerevisiae, under any number of tissue-specific promoters, 
that encourages gene expression and (2) the responsive line have “upstream activating 
sequences” (UAS) which are the DNA-binding sites of the Gal4 protein positioned next 
to a gene of interest. Through a number of approaches, a selected gene is located close, 
usually immediately “downstream”, to the UAS sequences, along with a selectable 
marker to monitor the presence or absence of the transgene. In the absence of the Gal4 
protein the responsive transgene is inactive. Thus, after crossing the parental, the 
directing and the responding, lines, the critical class progeny contains the Gal4 transgene 
and UAS target gene which can be now activated by the activity of the Gal4 protein 
(Phelps & Brand, 1998). This system induces the overexpression or inhibition of the 
gene of interest in the transgenic organism in our desired tissue (Sosa, De Gasperi, & 
Elder, 2012). For instance, by using GMR (glass multiple receptor) transgene in the 
Gal4/UAS system, a specific gene can be expressed in the developing D. melanogaster 
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eye and the resultant organ can be analyzed (Jeibmann & Paulus, 2009). Studying gain 
of function and loss of function phenotypes of the gene of interest in D. melanogaster 
can provide profound insight about underlying mechanisms in a particular disease.  
Another extremely valuable method that has been used in combination with the 
Gal4/UAS system is directed double-stranded RNA interference (RNAi) in which the 
expression of a gene is inhibited by RNA interference and the phenotypic effect analyzed 
(Armstrong, Texada, Munjaal, Baker, & Beckingham, 2006). In an RNA-degrading 
mechanism, a ribonuclease III enzyme, also known as Dicer, was identified in D. 
melanogaster which can produce fragments of 22 nucleotides (Bernstein, Caudy, 
Hammond, & Hannon, 2001). It is interesting to know that these nucleases are conserved 
in worms, flies, fungi, and mammals (Agrawal et al., 2003). The single-stranded short 
interfering fragments, siRNAs, then are integrated into the RNA-induced silencing 
complex (RISC). RISC will degrade its complementary mRNA throughout the 
cytoplasm (Armstrong et al., 2006). By preventing the translation of particular mRNA, 
the expression of the corresponding gene is silenced so that the loss-of-function 
phenotype can be created which is of great importance in the study of different cellular 
pathways. 
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Figure 1. Drosophila melanogaster eye: a scanning electron micrograph of GMR-
Gal4; UAS-lacZ. The genotype of the induvial picture is GMR-Gal4; UAS-lacZ. Even 
shaped ommatidia and a number of interommatidial bristles can be observed via this 
image of a healthy fly taken by FEI MLA 650F scanning electron microscope (500x 
magnification). 
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Figure 2. The Gal4/UAS two part directed expression transgenic system. A line 
encoding the yeast transcription activator protein Gal4 is crossed with a derivative line 
bearing the Upstream Activation Sequence (UAS); Gal4 protein specifically binds to this 
sequence to activate gene transcription. Gene expression is regulated in a time-specific 
and tissue-specific manner by promoter or enhancer sequences upstream of Gal4, and 
the progeny will correspondingly express the gene downstream of the UAS sequences 
(Neckameyer & Argue, 2012). Image was created in draw.io program.
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PTPRH homologues in Drosophila melanogaster  
When the desired gene has been identified as a disease gene, bioinformatics 
searches of the well-characterized genome of D. melanogaster can easily recognize one 
or more potential homologues (Staveley, 2012). Ptp10D and Ptp4E are two homologues 
of PTPRH in D. melanogaster which are the product of gene duplication. They are 
characterized by the presence of three to eight FN III repeats as well as three 
immunoglobulins in extracellular domain, a single PTP cytoplasmic domain, and a 
single transmembrane domain (Oliva et al., 2016). Following their similarity, Ptp10D 
and Ptp4E share 89% identity in their catalytic domains which is reduced to 40% 
compared to other RPTPs (Oliva & Hassan, 2017). Both genes are located on the X 
chromosome and Ptp4E has one less intron than Ptp10D. Ptp4E is duplicated from 
Ptp10D and is peculiar to drosophilid species. Non-drosophilid species have only one 
RPTP matching to Ptp4E/Ptp10D which is more similar to the ancestral gene, Ptp10D 
(Jeon, Nguyen, Bahri, & Zinn, 2008). Potential common functions are likely due to the 
similarity in the proteins’ structures. 
There are six RPTP genes in D. melanogaster which are all expressed in CNS 
neurons (Sun, Bahri, Schmid, Chia, & Zinn, 2000). RPTPs and tyrosine kinases (TKs) 
are essential in the pathways related to cell growth and neuronal growth cone guidance 
(Arzan Zarin & Labrador, 2019). However, they regulate these pathways in the opposite 
way. In cell growth pathways, TKs are receptors and phosphatases are cytoplasmic 
modulators, while their role in neuronal guidance pathways is vice versa (Jeon et al., 
2008). Ptp4E is ubiquitously expressed in late stages of embryonic development, 
whereas Ptp10D expression is limited to CNS axons in late embryos (Yang, Seow, 
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Bahri, Oon, & Chia, 1991). It is found that Ptp4E protein is closely related to Ptp10D 
due to their partial functional redundancy especially for nervous system phenotypes 
(Tao et al., 2019). It has been shown that knockdown of Ptp10D alone in Drosophila 
has not shown any defects in the embryo. Whereas, double mutants with other members 
of RPTP family, Ptp69D, produces LOF phenotypes in motor axon guidance which is a 
crucial step of neural development. Moreover, triple and quadruple LOF mutation of 
Ptp10D with other RPTP shows severe defects in motor neurons (Arzan Zarin & 
Labrador, 2019). Later studies have shown that there are no visible phenotypes in Ptp4E 
single mutants which can be explained by compensation by Ptp10D. However, double 
mutant embryos in which Ptp10D and Ptp4E both are genetically removed have not 
shown viability and died at hatching stage, but specific phenotypes related to CNS and 
tracheal cells have been detected (Jeon et al., 2008). These deficiencies have been 
observed in the formation of longitudinal axons which can be recovered by Ptp4E 
expression in neurons (Oliva & Hassan, 2017). Existing evidence for Ptp4E and Ptp10D 
having roles in neural growth and development is of great importance in studying PD 
etiology. 
A recent study with the emphasis of identification of new PD candidate genes, 
by using loss of function RNAi stocks for Ptp10D and Ptp4E within the Drosophila α-
synuclein transgenic model system, provided classical LOF alleles for both genes. By 
screening the results, severe effects on α-synuclein-induced degeneration in the retina 
were observed in Ptp10D/RNAi lines. Although, just one of two available RNAi lines 
for Ptp4E met their threshold criteria (Jansen, et al., 2017). Interestingly, heterozygosity 
of each gene in isolation did not show an increase in α-synuclein dependent retinal 
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degeneration but trans-heterozygosity for strong alleles showed a substantial 
enhancement which is consistent with the overlapping functions of these two genes in 
D. melanogaster (Jansen, et al., 2017). It is necessary to investigate both genes to 
understand the association with PD. 
 
Goals and objectives 
The central goal of this study is to explore the association between the Ptp10D 
and Ptp4E genes and Parkinson disease by means of a variety of techniques: 
bioinformatics analyses to examine the conservation of the PTPRH protein and, 
therefore, likely conserved function, biometric analyses of the eye to determine if a 
neurodevelopmental affect can be assigned to altered expression, and longevity and 
locomotor ability over time to evaluate the potential to model PD in flies with altered 
PTPRH activity. 
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Materials and methods 
Bioinformatics analysis 
Identification of the homologue of human PTPRH in Drosophila melanogaster 
The National Center for Biotechnology Information (NCBI) database 
(https://www.ncbi.nlm.nih.gov) was used to identify the amino acid sequence of human 
PTPRH (Accession number: XP_016882545). In the next step, by using the retrieved 
protein query from NCBI in tBLASTn search tool (https://blast.ncbi.nlm.nih.gov/), two 
homologues in Drosophila melanogaster were identified as Ptp4E and Ptp10D. The 
accession numbers are respectively NP_001162671.2 and NP_001259453.1. 
 
Identification of additional homologues and conserved domains and creation of a 
multiple alignment 
Since two homologues were found for PTPRH in D. melanogaster, just Ptp10D 
was considered in the multiple alignments due to its longer sequence. Besides, it has 
been shown that Ptp10D is the ancestor gene (Jeon et al., 2008). The FASTA format of 
Drosophila melanogaster Ptp10D protein query with the accession number of 
AGB95296.1 was obtained from the National Center for Biotechnology Information 
(NCBI). tBLASTn, which is one of the basic local alignment search tools, was employed 
to recognize the homologues of D. melanogaster Ptp10D in vertebrates and 
invertebrates. Amongst the available isoforms, the one with the highest coverage 
percentage in the query and highest total score was chosen as the homologue of this 
26 
 
gene. By using the Clustal Omega program (https://www.ebi.ac.uk/Tools/msa/clustalo/) 
a multiple sequence alignment was done to show the similarity among the proteins. 
Conserved domains for each sequence were identified by NCBI conserved domains 
database and Pfam (Sanger Institute) (https://pfam.xfam.org).The accession numbers of 
protein queries used in the alignment are as following: Drosophila melanogaster 
Ptp10D (accession number NP_001259453), Homo sapiens PTPRH (accession number 
XP_016882545.1), Mus musculus PTPRH (accession number NP_997153.2), Pan 
troglodytes PTPRH (accession number XP_009434687.3), Culex quinquefasciatus 
Ptp10D (accession number XP_001847466.1), and Aedes aegypti Ptp10D (accession 
number XP_021705337.1). 
 
D. melanogaster culturing and crosses 
D. melanogaster stocks 
In this study the control responder line, UAS-lacZ, and all the Gal4-bearing 
transgenic lines, which are GMR-Gal4, TH-Gal4, DDC-Gal4, and D42-Gal4, were 
obtained from the Bloomington Drosophila Stock Center (Indiana University, IN, USA). 
There were five experimental lines related to Ptp10D gene; one overexpression line and 
four inhibition lines, including UAS-Ptp10D-RNAv8010 (II), UAS-Ptp10D-RNAiv1104, and 
UAS-Ptp10D-RNAiKK101775 were purchased from Vienna Drosophila Resource Center in 
Vienna, Austria. For Ptp4E, the two inhibition lines were obtained from Bloomington 
Drosophila Stock Centre. 
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D. melanogaster media 
A standard Drosophila medium was used to keep Drosophila melanogaster 
stocks properly. This media consists of 65g/L cornmeal, 15 g/L yeast, 5.5 g/L agar and 
50ml/L fancy grade molasses in water with 5 ml of 0.1 g/mL methyl paraben in ethanol 
and 2.5 mL of propionic acid to prevent mold growth. Afterward, 7 ml of medium was 
poured to each vial to solidify and then stored at 4 to 6°C. The medium was produced 
by Dr. Brian E. Staveley approximately twice a month. 
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Table 2: Genotypes of all stocks used in this research 
 
Genotype Abbreviation Expression 
Pattern 
Reference 
Control line    
w; UAS-lacZ4-1-2 UAS-lacZ --- (Brand & 
Perrimon, 
1993) 
Experimental lines    
w[1118] 
P{w[+mC]=EP}Ptp10D[EP1172] 
UAS-
Ptp10DEP1172 
--- (Rorth et al., 
1998) 
y[1] sc[*] v[1]; P{y[+t7.7] 
v[+t1.8]=TRiP.HMS01917}attP2 
UAS-Ptp10D-
RNAiHMS01917 
--- (Perkins, et 
al., 2015) 
P{KK101775}VIE-260B UAS-Ptp10D-
RNAiKK101775 
--- (Dietzl et al., 
2007)  
w[1118]; P{GD115}v1104/TM3 UAS-Ptp10D-
RNAiv1104 
--- (Dietzl et al., 
2007) 
w[1118]; P{GD2611}v8010 UAS-Ptp10D-
RNAv8010 
--- (Dietzl et al., 
2007) 
y[1] sc[*] v[1]; P{y[+t7.7] 
v[+t1.8]=TRiP.HMS01838}attP2 
UAS-Ptp4E-
RNAiHMS01838 
--- (Dietzl et al., 
2007) 
y[1] v[1]; P{y[+t7.7] 
v[+t1.8]=TRiP.HMS05000}attP40 
UAS-Ptp4E-
RNAiHMS05000 
 (Perkins, et 
al., 2015) 
Transgenic lines    
w; GMR-GAL412  GMR-Gal4 Eye (Freeman, 
1996) 
w1118; P{Ddc-GAL4.L}4.3D DDC-Gal4 Neuron (Li, Chaney, 
Forte, & 
Hirsh, 2000) 
w*; P{ple-GAL4.F}3 TH-Gal4 Dopaminergic 
neuron 
(Friggi‐
Grelin, Iche, 
& Birman, 
2003) 
w[*]; P{w[+mW.hs]=GawB}D42 D42-Gal4 Motor neuron (Yeh, 
Gustafson, & 
Boulianne, 
1995) 
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Drosophila melanogaster crosses 
The appropriate temperature for storing the stocks is room temperature (typically 
20 to 22°C). The desired genotype, often composed of UAS or Gal4, was considered 
when choosing the male and female Drosophila melanogaster for breeding. For all the 
crosses virgin females and males were obtained respectively from experimental UAS-
bearing responder l lines and Gal4-containing transgenic lines. Matings were carried out 
upon fresh media after virgin females were isolated, every 8 to 12 hours and males were 
24 hours. For the mating process, 3 to 5 females and 2 to 3 males were introduced to 
each mating vial. Flies were then transferred onto fresh media three times for every 2 to 
3 days for more productive matings. As soon as eclosion had taken place, paternal flies 
were discarded, and the male progeny of the critical class were collected. Since a UAS-
Ptp4E-RNAiHMS05000 bearing line possesses the CyO balancer chromosome, careful 
consideration was given when collecting respective critical class males, and the 
progenies with Curly wings were all discarded. 
Biometric analysis of the Drosophila melanogaster compound eye 
The effects on the number of ommatidia and interommatidial bristles were 
determined by detailed biometric analysis of the D. melanogaster compound eye. As 
eclosure occurs, the critical class male progeny resulted from the selected crosses were 
collected and matured for 3 to 5 days in groups of 20 or less upon standard Drosophila 
medium at room temperature. The flies were frozen at -80°C, and eventually thawed and 
finally placed upon aluminium Scanning Electron Microscopy studs. Using forceps, the 
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flies were carefully placed on their right side so that the left eye would face upwards. 
Approximately 20 flies of each critical class were prepared and imaged. Scanning 
electron microscope photography was carried out after 48 hours of sample desiccation. 
The Mineral Liberation Analyzer 650F was employed to scan the left eye of every single 
male fly. Ten images were chosen as a sample for each cross, which had the best quality 
and clarity, and then the image analysis was done by the software program ImageJ 
(https://imagej.nih.gov/ij/) by counting the number of ommatidia and interommatidial 
bristles with cell counter. Graphpad Prism 8 (Graphpad Software Inc.) was used in order 
to analyze obtained data as well as the calculation of mean ± standard error of the mean. 
Parametric statics were utilized for the analysis since the data was obtained randomly 
from a normal distribution. By means of unpaired T-test (two-tailed), significant 
differences between crosses were determined. Results were considered statistically 
significant where the p-value was less than 0.05. 
 
Behavioural Assays 
Ageing assay 
To study the life span of selected critical class flies in comparison with control 
(unaffected) flies, a survival analysis was carried out. Initially, the male progeny of the 
critical classes were collected from each cross under gaseous carbon dioxide (CO2) on 
a daily basis. The flies were maintained under ideal conditions, with up to 20 flies per 
vial to prevent overcrowding and on fresh standard medium at 25°C. This process 
continued until the collection of approximately 300 male critical class flies per cross 
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which typically took one to three weeks depending on the experiment. On the second 
day after the collection of flies the observation began in which the number of dead flies 
was recorded. Flies are considered to be dead when there was no movement detected 
(Staveley et al., 1990).  The vials were scored every two days until the last fly in the 
cohort was dead. The medium was changed whenever there was a dead fly in the vial as 
well as no less than twice a week to maintain ideal condition for all remaining flies. All 
the data then transferred to Graphpad Prism 8 (Graphpad Software Inc.) and then 
survival curves were analyzed by using the log-rank test with significance considered at 
p < 0.05 with Bonferroni correction. 
 
Locomotion assay 
The motor control of flies was studied during their life span through a locomotor 
analysis which involved collecting 70 critical class male progeny flies from each 
breeding on the same day of eclosure, distributing and maintaining in seven vials (ten 
flies per each vial) and then transferring them to a new medium twice a week over the 
period the experiment. To maintain ideal conditions, all the vials were kept at 25°C. 
Beginning with one week after collection; the ability of flies to climb was assessed every 
seven days. Each group consisting of ten flies per genotype underwent ten trials to make 
a total of 500 trials per week. Each trial lasted for 10 seconds during which I actively 
observed the tube to record the data. A 1.5-cm diameter glass tube with a length of 30 
cm was used to determine climbing ability which was gauged by reaching or surpassing 
2 cm intervals of the glass tube, as described by Todd and Staveley, 2008. The 
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measurement of climbing ability was repeated every seven days. The index was 
calculated through the equation: Climbing index = Σ nm/N where n is the number of 
flies at a given level, m is the score of the level which is between one and five and N is 
the total number of flies climbed in that trial. These data were analyzed by the software 
GraphPad Prism 8 (GraphPad Software Inc.). Finally, a nonlinear regression curve was 
used to show the analysis of 5-climbing index as a function of time for each genotype 
with 95% confidence intervals within a graph. The decrease in climbing ability is shown 
when there is a slope in the graph and the initial climbing ability is represented by Y-
intercept. Both parameters are calculated for each curve. Slopes of the curves were 
compared using a 95% confidence interval and they were considered statistically 
significant where the p-value was  0.05. 
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Results 
Bioinformatics analysis 
Identification of PTPRH homologues in Drosophila melanogaster and conserved 
domains 
The amino acid sequence of Homo sapiens PTPRH protein was obtained from 
NCBI (XP_016882545.1). A tBLASTn search was conducted on the D. melanogaster 
genome and PTP10D and PTP4E genes, which are the product of a gene duplication, 
were identified as the most similar ones compared to PTPRH. The alignment shows that 
the percentage of query covered by the database sequence for Ptp10D and PTP4E 
proteins are 90% and 89%, respectively. The highest percent identity of the queries for 
Ptp10D is 44.03%, and for Ptp4E it is 43.97%. The multiple alignment of these three 
sequences in Clustal Omega shows that the Protein-tyrosine phosphatase (PTP) domain 
and Fibronectin type III (FN3) domains are conserved between each of these proteins in 
D. melanogaster and PTPRH in human (Figures 3 & 4). 
 
The PTPRH protein is conserved between vertebrates and invertebrates 
To conduct a multiple alignment of the PTPRH proteins from vertebrates and 
invertebrates, sequences from D. melanogaster (NP_001259453), Culex 
quinquefasciatus (XP_001847466.1), Aedes aegypti (XP_021705337.1), Homo sapiens 
(XP_016882545.1), Mus musculus (NP_997153.2), and Pan troglodytes 
(XP_009434687.3) were used. These sequences were identified by tBLASTn search. 
The alignment shows that the Protein-tyrosine phosphatase (PTP) domain and FN(III) 
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domains are conserved in both vertebrates and invertebrates. However, there are some 
domains related to FN3 repeats that were specific to either invertebrates or vertebrates 
(Figure 5). The illustration in Figure 6 shows the conserved domain between the PTPRH 
protein in H. sapiens and its homologues in D. melanogaster: Ptp10D and Ptp4E. 
Ptp10D is the longest protein (1653 aa) with nine FN3 domains and one PTP domain, 
which is the longest domain and is completely conserved between all species. Ptp4E 
with 1615 aa length has eight FN3 domains and one PTP domain. PTPRH is the shortest 
protein (1137 aa) with six FN3 domains and one PTP domain.  
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Figure 3: Alignment of human PTPRH with Drosophila melanogaster Ptp10D 
Highlighted regions represent fibronectin type III (FN3) domains except the last highlighted 
region (pink) which is protein tyrosine phosphatase (PTP) domain. Protein sequences obtained 
from BLAST and conserved domains of each sequence obtained from Pfam. ‘‘*’’ indicates fully 
conserved amino acids in aligned sequences. ‘‘:’’ indicates conserved amino acid with less 
similar properties and ‘‘.’’ indicates semi-conserved substitutions.  
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Figure 4: Alignment of human PTPRH with Drosophila melanogaster Ptp4E 
Highlighted regions represent fibronectin type III (FN3) domains except the last highlighted 
region (pink) which is protein tyrosine phosphatase (PTP) domain. Protein sequences obtained 
from BLAST and conserved domains of each sequence obtained from Pfam. ‘‘*’’ indicates fully 
conserved amino acids in aligned sequences. ‘‘:’’ indicates conserved amino acid with less 
similar properties and ‘‘.’’ indicates semi-conserved substitutions. 
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Figure 5: PTPRH is well-conserved in vertebrates and invertebrates. Clustal Omega 
multiple alignment of PTPRH protein in vertebrates and Ptp10D in invertebrates. 
Highlighted regions are FN3 domains except the last region in pink which is the longest 
domain is PTP domain. “*” indicates amino acids that are identical in all sequences in 
the alignment. “:” indicates conserved substitutions. “.” indicates semi-conserved 
substitutions. 
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Figure 6: Comparison of D. melanogaster Ptp10D (A), Ptp4E (B) proteins, with 
Homo sapiens PTPRH protein (C) with coloured conserved domains. Coloured 
rectangles represent fibronectin type III (FN3) domains except for the last highlighted 
region (black) which is protein tyrosine phosphatase (PTP) domain. 
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Biometric analysis of the compound eye 
Effects of the inhibition and overexpression of Ptp10D and inhibition of Ptp4E 
during development of eye of D. melanogaster 
The eye of D. melanogaster is a highly effective model system to use to analyze 
molecular interactions and developmental mechanisms of the nervous system (Arzu, et 
al., 2013). It is made up of approximately 800 units designated as ommatidia under 
normal developmental conditions.  Measuring the neurodegeneration is feasible through 
the eye structure due to the existence of a large number of neurons, more than 6000, 
make it very convenient for observing changes in phenotypes (Frankfort, et al., 2002). 
By using the GMR transgene in the Gal4/UAS system, we can inhibit or overexpress our 
desired gene in the eye of D. melanogaster and analyze the results. Certain parameters 
can be analyzed to study the impacts of changes in the development process including 
the ommatidia number, interommatidial bristle number, ommatidia area, and eye area. 
To determine the phenotypic changes in the eye due to altering Ptp10D and Ptp4E 
expression, a biometric analysis was carried out (Figure 8 & 9). Changes in the numbers 
of ommatidia and bristles for each derivative line were compared to the control (GMR-
Gal4; UAS-lacZ). A summary of the ommatidia and bristle numbers is shown in Table 
3 & 4, respectively. Biometric analysis of the scanning electron micrographs showed 
that eye-specific inhibition of Ptp10D and Ptp4E decreased the number of ommatidia in 
eye (Figure 8). Inhibition of RNAikk101775 had the most significant decrease amongst other 
Ptp10D inhibition transgenic lines (ommatidia mean number per eye: 666.4 ± 8.713). 
Between two available inhibition lines for Ptp4E, RNAiHMS01838, with a median 
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ommatidia number of 648.8 ± 8.155 had the most substantial decrease. This is compared 
to the control UAS-lacZ in which the median number of ommatidia per eye was 710.3 ± 
3.330. There is only one RNAi line, RNAi v8010, for Ptp10D which did not have 
significant changes based on its p-value. The number of ommatidia per eye for this 
transgenic line was 695.9 ± 7.213 (Table 3).  
The inhibition of Ptp4E and Ptp10D with the transgene GMR-GAL4 led to a 
significant decrease in interommatidial bristle number (Figure 9). The range of the 
average bristle number per eye was from 221.5 ± 40.26 to 577.2 ± 8.711 for inhibition 
lines of Ptp10D in which the most significant decrease belonged to RNAiHMS01917. The 
average bristle number for Ptp4E-RNAiHMS01838 and Ptp4E-RNAiHMS05000 were 105 ± 
10.36 and 344.9 ± 9.914, respectively. These were compared to the control line, UAS-
lacZ, where the average number of bristle per eye were631.2 ± 6.93 (Table 4). The 
overexpression of Ptp10D significantly decreased the ommatidia and bristle number. By 
using Ptp10DEP1172, the overexpression line under the control of the GMR-Gal4 
transgene, the average number of ommatidia and bristle number per eye decreased to a 
median value of 662.2 ± 4.800 and 300 ± 8.955, respectively, compared to 710.3 ± 3.330 
and 631.2 ± 6.93, which were the average number of ommatidia and interommatidial 
bristle, respectively, for the control UAS-lacZ. 
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Figure 7: Inhibition and overexpression of Ptp10D and inhibition of Ptp4E 
significantly decreased the number of ommatidia and interommatidial bristles of 
D. melanogaster. Scanning electron micrographs of A: GMR-GAL4; UAS-lacZ, B: 
GMR-Gal4; UAS-Ptp10DEP1172 C: GMR-Gal4; UAS-Ptp4E-RNAiHMS01838, and D: GMR-
Gal4; UAS-Ptp10D-RNAi HMS01917. 
 
  
B 
C D 
A 
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Figure 8: Biometric analysis of the consequences of inhibition and overexpression 
of Ptp10D and inhibition of Ptp4E during development of the D. melanogaster 
Drosophila compound eye. Inhibition of Ptp10D (four lines) and Ptp4E (two lines) 
significantly decreased ommatidia number in the compound eye. There is only one 
overexpression line for Ptp10D which showed a significant decrease as well. The 
changes in ommatidia number are not significant in the inhibition line UAS-Ptp10D-
RNAi v8010. Significance is p<0.05 as compared to control group UAS-lacZ. 
 
 
 
 
 
 
 
 
Table 3. Summary of the biometric analysis of ommatidia number when Ptp10D is 
inhibited and overexpressed and Ptp4E is inhibited during the development of the 
compound eye directed by GMR-Gal4. 
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Genotype Sample 
Size (n) 
Mean ± 
SEM 
P-value 
compared 
to control 
Significant 
GMR-Gal4; UAS-lacZ 
(control) 
10 710.3 ± 
3.330 
N/A N/A 
GMR-Gal4; UAS-
Ptp10D-RNAikk101775 
(inhibition) 
10 666.4 ± 
8.713 
<0.0001 Yes 
GMR-Gal4; UAS-
Ptp10D-RNAi v8010 
(inhibition) 
10 695.9 ± 
7.213 
0.0613 No 
GMR-Gal4; UAS-
Ptp10D-RNAi HMS01917 
(inhibition) 
10 692.7 ± 
6.987 
0.0215 Yes 
GMR-Gal4; UAS-
Ptp10D-RNAi v1104 
(inhibition) 
10 683.4 ± 
4.445 
<0.0001 Yes 
GMR-Gal4; UAS-
Ptp10DEP1172 
(overexpression) 
10 662.2 ± 
4.800 
<0.0001 Yes 
GMR-Gal4; UAS-Ptp4E-
RNAiHMS01838 
(inhibition) 
10 648.8 ± 
8.155 
<0.0001 Yes 
GMR-Gal4; UAS-Ptp4E-
RNAiHMS05000 
(inhibition) 
10 665.3 ± 
4.789 
<0.0001 Yes 
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Figure 9: The effect of inhibition and overexpression of Ptp10D and inhibition of 
Ptp4E upon the development of interommatidial bristle number in the Drosophila 
compound eye. Loss-of-function of Ptp10D and Ptp4E lead to a significant decrease in 
interommatidial bristle number compared to the control UAS-lacZ in all experimental 
liness. Overexpression of Ptp10D also resulted in a significant decrease in bristle 
number. Based on t-tests, which were used to analyzing data, p-values less than 0.05 
were considered significant. Error bars show the standard error of the mean. 
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Table 4. Summary of the biometric analysis of interommatidial bristle number 
when Ptp10D is inhibited and overexpressed and Ptp4E is inhibited during the 
development of the compound eye.  
 
 
 
 
 
 
 
 
 
 
 
 
Genotype Sample 
Size (n) 
Mean ± SEM P-value 
compared 
to control 
Significant 
GMR-Gal4; UAS-lacZ 
(control) 
10 631.2 ± 6.93 N/A N/A 
GMR-Gal4; UAS-
Ptp10D-RNAikk101775 
(inhibition) 
10 551 ± 7.993 <0.0001 Yes 
GMR-Gal4; UAS-
Ptp10D-RNAi v8010 
(inhibition) 
10 342.8 ± 17.89 <0.0001 Yes 
GMR-Gal4; UAS-
Ptp10D-RNAi HMS01917 
(inhibition) 
10 221.5 ± 40.26 <0.0001 Yes 
GMR-Gal4; UAS-
Ptp10D-RNAi v1104 
(inhibition) 
10 577.2 ± 8.711 <0.0001 Yes 
GMR-Gal4; UAS-
Ptp10DEP1172 
(overexpression) 
10 300 ± 8.955 <0.0001 Yes 
GMR-Gal4; UAS-Ptp4E-
RNAiHMS01838 
(inhibition) 
10 105 ± 10.36 <0.0001 Yes 
GMR-Gal4; UAS-Ptp4E-
RNAiHMS05000 
(inhibition) 
10  344.9 ± 9.914 <0.0001 Yes 
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Table 5. Summary of biometric analyses of ommatidia and interommatidial bristle 
number. For these analyses an eye-specific transgenic line GMR-Gal4 was crossed to 
Ptp10D and Ptp4E responder lines. 
 
Responder lines Transgenic line 
Inhibition GMR-Gal4 
Ommatidia number Bristle number 
UAS-Ptp10D-RNAikk101775 Significant Decrease Significant Decrease 
UAS-Ptp10D-RNAi v8010 No significant 
change 
Significant Decrease 
UAS-Ptp10D-RNAi HMS01917 Significant Decrease Significant Decrease 
UAS-Ptp10D-RNAi v1104 Significant Decrease Significant Decrease 
Overexpression  
UAS-Ptp10DEP1172 Significant Decrease Significant Decrease 
Inhibition  
UAS-Ptp4E-RNAiHMS01838 Significant Decrease Significant Decrease 
UAS-Ptp4E-RNAi HMS05000 Significant Decrease Significant Decrease 
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Effects of the inhibition of Ptp10D on D. melanogaster 
Inhibition of Ptp10D decreases climbing ability and lifespan 
The main hallmark of PD is a progressive degeneration of dopaminergic neurons. 
Using different kinds of drivers allows us to study the effects of Ptp10D on selected 
dopaminergic neurons. To investigate the impact of the LOF of Ptp10D on the climbing 
ability and lifespan of D. melanogaster, the motor neuron specific transgenic line D42-
Gal4, the neuron-specific transgenic line DDC-Gal4, and the dopaminergic neuron-
specific transgenic line TH-Gal4 were used in the Gal4/UAS system. The ageing assay 
was carried out in parallel with climbing analysis for all drivers to identify the changes 
in the climbing ability due to premature senescence. The survival curves in Figure 10 
show that the loss of function of Ptp10D using D42-Gal4 transgene significantly 
decreased the lifespan, except for Ptp10D-RNAikk101775 flies in which the changes were 
not considerably different (P-value: 0.1860) compared to the lacZ-expressing controls. 
The median lifespan for Ptp10D-RNAiv1104, Ptp10D-RNAi v8010, and Ptp10D-RNAi 
HMS0191 were 50, 54, and 58 days, respectively. While the control flies live for an average 
of 66 days (Table 6). The climbing ability for these experimental lines significantly 
differed from the control UAS-lacZ when using the motor neuron specific driver D42-
GAL4 with a P-value of <0.0001 for all lines (Figure 11). The most significantly 
different climbing curve belonged to D42-Gal4; UAS-Ptp10D-RNAi HMS01917 with a 95% 
confidence interval of 0.03173 – 0.04704 compared to 0.03699 – 0.04897 for D42-Gal4; 
UAS-lacZ (Table 7).  
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When different inhibition lines of Ptp10D were expressed in flies through the 
DDC-Gal4 transgene, which is a neuron-specific line, extensive changes occurred in 
their lifespan (Figure 12). The median survival for control flies, DDC-Gal4; UAS-lacZ, 
was 72 while it decreased to 56, 54, and 50 for Ptp10D-RNAi v8010, Ptp10D-RNAi v1104, 
and Ptp10D-RNAi HMS01917 flies, respectively (Table 8). Interestingly, DDC-Gal4; UAS-
Ptp10D-RNAi HMS01917 flies with the shortest median lifespan showed the lowest 
climbing ability amongst all Ptp10D inhibition lines as well (Figure 13). The 95% 
confidence intervals for this line was 0.02649 – 0.0371 compared to 0.04563 – 0.05455 
for DDC-Gal4; UAS-lacZ (Table 9). The p-value for all lines were <0.0001 except for 
DDC-Gal4; UAS-Ptp10D-RNAikk101775 which was 0.0084 and less significant than the 
others.  
Survival curves for transgenic lines with dopaminergic neuron specificity shows 
significant differences between experimental lines and the control line TH-Gal4; UAS-
lacZ (Figure 14). The Median survival for the control group was 72 and it decreased to 
68, 60, 62, and 58 for Ptp10D-RNAikk101775, Ptp10D-RNAi HMS01917, Ptp10D-RNAi v8010, 
and Ptp10D-RNAi v1104, respectively (Table 10). By comparing the median lifespan 
between DDC and TH inhibition lines, it becomes clear that the decrease in the flies’ 
lifespan is more significant when it comes to DDC transgene considering that the median 
survival was 72 days for the control group of both drivers. The climbing curves indicate 
that all transgenic flies using the TH transgene experienced a decrease in their climbing 
ability in which Ptp10D-RNAi HMS01917 had the most significant decrease compared to 
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the control line (Figure 15). The 95% confidence intervals for this line was 0.03984 – 
0.05256 in comparison to 0.04104 – 0.05848 in control flies (Table 11). 
 
Effects of the overexpression of Ptp10D  
Overexpression of Ptp10D decreases climbing ability and longevity 
To assess the effects of the overexpression of Ptp10D on the longevity and 
climbing ability of D. melanogaster, the motor neuron-specific transgenic line D42-
Gal4, the neuron-specific transgenic line DDC-Gal4, and the dopaminergic neuron-
specific transgenic line TH-Gal4 were used. When using D42-Gal4 transgene a 
significant decrease was observed in the lifespan of flies (Figure 16). In this 
overexpression line, D42-Gal4; UAS- Ptp10DEP1172, the median lifespan decreased to 
54 from 66 in D42-Gal4; UAS-lacZ (Table 12). In addition to longevity, the climbing 
ability was reduced significantly (Figure 17). As is shown in Table 13 the 95% 
confidence intervals for UAS-lacZ and Ptp10DEP1172 were 0.03699 – 0.04897 and 
0.02972 – 0.04550, respectively. 
The most significant change in the longevity of Ptp10D overexpressing flies was 
related to the neuron-specific transgenic line DDC-Gal4 (Figure 18). The median 
survival in DDC-Gal4; UAS-lacZ was 72 days which remarkably decreased to 46 in 
DDC-Gal4; UAS-Ptp10DEP1172 (Table 14). Moreover, the decreases in climbing ability 
by using the DDC-Gal4 transgenic line can be seen in Figure 19. Based on the t-test 
analysis the 95% confidence intervals for Ptp10DEP1172 was 0.03409 – 0.04520 
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compared to 0.04563 – 0.05455 for UAS-lacZ (Table 15). The climbing and ageing assay 
for the overexpression of Ptp10D were repeated with the TH-Gal4 transgene which led 
to a significant decrease in both parameters. (Figure 20 and 21). The median lifespan of 
TH-Gal4; UAS-Ptp10DEP1172 was 54 days based on the log-rank analysis compared to 
72 days in control flies (Table 16). 
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Figure 10: Inhibition of Ptp10D using a motor neuron-specific transgene (D42-
Gal4) causes a significant decrease in longevity. Four different inhibition lines were 
used. All of them except Ptp10D-RNAikk101775 (II) were significant compared to control 
D42-Gal4; UAS-lacZ. Longevity is shown by percent survival. Significance is p < 0.05 
and error bars shows the standard error of the mean. 
 
 
 
Table 6. Comparison of the longevity of flies for the inhibition of Ptp10D in motor 
neurons by Mantel-Cox Log-rank statistics. Chi-square values and p-values were 
calculated using UAS-lacZ controls. 
 
Genotype Number 
of flies 
Median 
Survival 
(days) 
Chi – 
square 
value  
P-value  Significa
nt 
D42-Gal4; UAS-
lacZ 
306 66 N/A N/A N/A 
D42-Gal4; UAS-
Ptp10D-RNAikk101775 
332 66 1.749 0.1882 No 
D42-Gal4; UAS-
Ptp10D-RNAi v8010 
300 54 239.2 <0.0001 Yes 
D42-Gal4; UAS-
Ptp10D-RNAi 
HMS01917 
292 58 106.0 <0.0001 Yes 
D42-Gal4; UAS-
Ptp10D-RNAi v1104 
324 50 331.0 <0.0001 Yes 
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Figure 11: Inhibition of Ptp10D using a motor neuron specific transgenic line (D42-
Gal4) causes a significant decrease in flies climbing ability over time. Four different 
inhibition lines were used. All of them were significant compared to control D42-Gal4; 
UAS-lacZ. Data was analyzed by a non-linear curve fit with 95% confidence intervals 
to determine significance. Error bars represent standard error of the mean. 
 
 
Table 7. Comparison of the climbing ability of flies for the inhibition of Ptp10D in 
motor neurons by using a non-linear regression curve for each inhibition line. 
Genotype 95% 
Confidence 
Intervals 
R2 P-value Significant 
D42-Gal4; UAS-lacZ 0.03699 – 
0.04897 
0.8735 N/A N/A 
D42-Gal4; UAS-
Ptp10D-RNAikk101775 
0.03761 – 
0.05105 
0.8653 <0.0001 Yes 
D42-Gal4; UAS-
Ptp10D-RNAi v8010 
0.03737 – 
0.06007 
0.7700 <0.0001 Yes 
D42-Gal4; UAS-
Ptp10D-RNAi HMS01917 
0.03173 – 
0.04704 
0.8262 <0.0001 Yes 
D42-Gal4; UAS-
Ptp10D-RNAi v1104 
0.03130 – 
0.04244 
0.8642 <0.0001 Yes 
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Figure 12: Inhibition of Ptp10D using a neuron-specific transgenic line (DDC-Gal4) 
causes a significant decrease in longevity. Four different inhibition lines were used 
and all of them were significant compared to control DDC-Gal4; UAS-lacZ. Longevity 
is shown by percent survival. Significance is p< 0.05 and error bars shows the standard 
error of the mean. 
 
 
Table 8. Comparison of the longevity of flies for the inhibition of Ptp10D DDC-Gal4 
expressing in neurons by Mantel-Cox Log-rank statistics. Chi-square values and p-
values were calculated using UAS-lacZ controls. 
Genotype Number 
of flies 
Median 
Survival 
(days) 
Chi – 
square 
value  
P-value  Significant 
DDC-Gal4; UAS-
lacZ 
299 72 N/A N/A N/A 
DDC-Gal4; UAS-
Ptp10D-RNAikk101775 
356 64 44.01 <0.0001 Yes 
DDC-Gal4; UAS-
Ptp10D-RNAi v8010 
300 56 305.2 <0.0001 Yes 
DDC-Gal4; UAS-
Ptp10D-RNAi 
HMS01917 
237 50 342.2 <0.0001 Yes 
DDC-Gal4; UAS-
Ptp10D-RNAi v1104 
348 54 306.6 <0.0001 Yes 
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Figure 13: Inhibition of Ptp10D using a neuron-specific transgenic line (DDC-Gal4) 
causes a significant decrease in flies climbing ability over time. Four different 
inhibition lines were used. All of them were significant compared to control DDC-Gal4; 
UAS-lacZ. Data was analyzed by a non-linear curve fit with 95% confidence intervals 
to determine significance. Error bars represent standard error of the mean. 
 
 
Table 9. Comparison of the climbing ability of flies for the inhibition of Ptp10D in 
neurons by using a non-linear regression curve for each inhibition line. 
 
  
Genotype 95% 
Confidence 
Intervals 
R2 P-value Significant 
DDC-Gal4; UAS-lacZ 0.04563 – 
0.05455 
0.9533 N/A N/A 
DDC-Gal4; UAS-
Ptp10D-RNAikk101775 
0.03929 – 
0.04888 
0.9262 0.0084 Yes 
DDC-Gal4; UAS-
Ptp10D-RNAi v8010 
0.06274 – 
0.09120 
0.8831 <0.0001 Yes 
DDC-Gal4; UAS-
Ptp10D-RNAi HMS01917 
0.02649 – 
0.03571 
0.8662 <0.0001 Yes 
DDC-Gal4; UAS-
Ptp10D-RNAi v1104 
0.04799 – 
0.07268 
0.8224 <0.0001 Yes 
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Figure 14: Inhibition of Ptp10D using a dopaminergic neuron specific driver (TH-
Gal4) causes a significant decrease in longevity. Four different inhibition lines were 
used and all of them were significant compared to control TH-Gal4; UAS-lacZ. 
Longevity is shown by percent survival. Significance is p< 0.05 and error bars shows 
the standard error of the mean. 
 
 
Table 10. Comparison of the longevity of flies for the inhibition of Ptp10D in 
dopaminergic neurons by Mantel-Cox Log-rank statistics. Chi-square values and p-
values were calculated using UAS-lacZ controls. 
Genotype Number 
of flies 
Median 
Survival 
(days) 
Chi– 
square 
value  
P-value  Significant 
TH-Gal4; UAS-lacZ 272 72 N/A N/A N/A 
TH-Gal4; UAS-
Ptp10D-RNAikk101775 
314 68 44.76 <0.0001 Yes 
TH-Gal4; UAS-
Ptp10D-RNAi v8010 
321 60 257.4 <0.0001 Yes 
TH-Gal4; UAS-
Ptp10D-RNAi 
HMS01917 
365 62 233.6 <0.0001 Yes 
TH-Gal4; UAS-
Ptp10D-RNAi v1104 
300 58 272.6 <0.0001 Yes 
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Figure 15: Inhibition of Ptp10D using a dopaminergic neuron specific transgenic 
line (TH-Gal4) causes a significant decrease in flies climbing ability over time. Four 
different inhibition lines were used. All of them were significant compared to control 
TH-Gal4; UAS-lacZ. Data were analyzed by a non-linear curve fit with 95% confidence 
intervals to determine significance. Error bars represent standard error of the mean. 
 
 
 
Table 11. Comparison of the climbing ability of flies for the inhibition of Ptp10D in 
dopaminergic neurons by using a non-linear regression curve for each inhibition 
line.  
Genotype 95% 
Confidence 
Intervals 
R2 P-value Significant 
TH-Gal4; UAS-lacZ 0.04104 – 
0.05848 
0.8594 N/A N/A 
TH-Gal4; UAS-
Ptp10D-RNAikk101775 
0.03413 – 
0.04385 
0.8933 0.0001 Yes 
TH-Gal4; UAS-
Ptp10D-RNAi v8010 
0.07946 – 
0.1160 
0.9149 <0.0001 Yes 
TH-Gal4; UAS-
Ptp10D-RNAi HMS01917 
0.03984 – 
0.05256 
0.9024 <0.0001 Yes 
TH-Gal4; UAS-
Ptp10D-RNAi v1104 
0.05782 – 
0.07365 
0.9370 <0.0001 Yes 
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Figure 16: Overexpression of Ptp10D using a motor neuron specific transgenic line 
(D42-Gal4) causes a significant decrease in longevity. Flies expressing UAS-
Ptp10DEP1172(X) were significant compared to control D42-Gal4; UAS-lacZ. Longevity 
is shown by percent survival. Significance is p< 0.05 and error bars shows the standard 
error of the mean. 
 
 
 
 
 
Table 12. Comparison of the longevity of flies for the overexpression of Ptp10D in 
motor neurons by Mantel-Cox Log-rank statistics. Chi-square values and p-values 
were calculated using UAS-lacZ controls. 
 
Genotype Number 
of flies 
Median 
Survival 
(days) 
Chi – 
square 
value  
P-value  Significant 
D42-Gal4; UAS-lacZ 306 66 N/A N/A N/A 
D42-Gal4; UAS-
Ptp10DEP1172 
297 54 205.9 <0.0001 Yes 
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Figure 17: Overexpression of Ptp10D using a motor neuron specific transgenic line 
(D42-Gal4) causes a significant decrease in flies climbing ability over time. Four 
different inhibition lines were used. All of them were significant compared to control 
D42-Gal4; UAS-lacZ. Data was analyzed by a non-linear curve fit with 95% confidence 
intervals to determine significance. Error bars represent standard error of the mean. 
 
 
 
 
Table 13. Comparison of the climbing ability of flies for the overexpression of 
Ptp10D in motor neurons by using a non-linear regression curve for each inhibition 
line. 
 
 
 
Genotype 95% 
Confidence 
Intervals 
R2 P-value  Significant 
D42-Gal4; UAS-lacZ 0.03699 – 
0.04897 
0.8735 N/A N/A 
D42-Gal4; UAS-
Ptp10DEP1172 
0.02972 – 
0.04550 
0.7840 <0.0001 Yes 
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Figure 18: Overexpression of Ptp10D using a neuron specific transgenic line (DDC-
Gal4) causes a significant decrease in longevity. Flies expressing UAS-Ptp10DEP1172 
were significant compared to control DDC-Gal4; UAS-lacZ. Longevity is shown by 
percent survival. Significance is p< 0.05 and error bars shows the standard error of the 
mean. 
 
 
 
 
Table 14. Comparison of the longevity of flies for the overexpression of Ptp10D in 
neurons by Mantel-Cox Log-rank statistics. Chi-square values and p-values were 
calculated using UAS-lacZ controls. 
 
 
 
 
Genotype Number 
of flies 
Median 
Survival 
(days) 
Chi – 
square 
value  
P-value  Significant 
DDC-Gal4; UAS-
lacZ 
299 72 N/A N/A N/A 
DDC-Gal4; UAS-
Ptp10DEP1172 
324 46 556.5 <0.0001 Yes 
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Figure 19: Overexpression of Ptp10D using a neuron specific transgenic line (DDC-
Gal4) causes a significant decrease in flies climbing ability over time. Four different 
inhibition lines were used. All of them were significant compared to control DDC-Gal4; 
UAS-lacZ. Data was analyzed by a non-linear curve fit with 95% confidence intervals 
to determine significance. Error bars represent standard error of the mean. 
 
 
 
 
Table 15. Comparison of the climbing ability of flies for the overexpression of 
Ptp10D in neurons by using a non-linear regression curve for each inhibition line. 
 
 
 
 
 
 
 
 
 
Genotype 95% 
Confidence 
Intervals 
R2 P-value  Significant 
DDC-Gal4; UAS-lacZ 0.04563 – 
0.05455 
0.9533 N/A N/A 
DDC-Gal4; UAS-
Ptp10DEP1172 
0.03409 – 
0.04520 
0.8846 <0.0001 Yes 
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Figure 20: Overexpression of Ptp10D using a dopaminergic neuron specific 
transgenic line (TH-Gal4) causes a significant decrease in longevity. Flies expressing 
UAS-Ptp10DEP1172 were significant compared to control TH-Gal4; UAS-lacZ. Longevity 
is shown by percent survival. Significance is p< 0.05 and error bars shows the standard 
error of the mean. 
 
 
 
Table 16. Comparison of the longevity of flies for the overexpression of Ptp10D in 
dopaminergic neurons by Mantel-Cox Log-rank statistics. Chi-square values and p-
values were calculated using UAS-lacZ controls. 
 
Genotype Number 
of flies 
Median 
Survival 
(days) 
Chi – 
square 
value  
P-value  Significant 
TH-Gal4; UAS-lacZ 272 72 N/A N/A N/A 
TH-Gal4; UAS-
Ptp10DEP1172 
301 54 383.5 <0.0001 Yes 
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Figure 21: Overexpression of Ptp10D using a dopaminergic neuron-specific 
transgenic line (TH-Gal4) causes a significant decrease in flies climbing ability over 
time. Four different inhibition lines were used. All of them were significant compared 
to control TH-Gal4; UAS-lacZ. Data were analyzed by a non-linear curve fit with 95% 
confidence intervals to determine significance. Error bars represent standard error of the 
mean. 
 
 
 
Table 17. Comparison of the climbing ability of flies for the overexpression of 
Ptp10D in dopaminergic neurons by using a non-linear regression curve for each 
inhibition line. 
 
 
 
 
 
Genotype 95% 
Confidence 
Intervals 
R2 P-value  Significant 
TH-Gal4; UAS-lacZ 0.04104 – 
0.05848 
0.8594 N/A N/A 
TH-Gal4; UAS-
Ptp10DEP1172 
0.04122 – 
0.07112 
0.7479 <0.0001 Yes 
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Effects of the inhibition of Ptp4E in D. melanogaster  
Loss of function of Ptp4E results in a reduction in longevity and climbing ability 
To identify the effect of Ptp4E inhibition in D. melanogaster, three different 
transgenic lines were used in the Gal4/UAS system: the motor neuron-specific transgene 
D42-Gal4, the neuron-specific transgene DDC-Gal4, and the dopaminergic neuron-
specific transgene TH-Gal4. When using the D42-Gal4 transgenic line, the most 
significant change in both ageing and climbing ability was for the Ptp4E-RNAiHMS01838 
inhibition line (Figure 22 & 23). As can be seen in Table 18, the median survival for 
Ptp4E-RNAiHMS01838 was 54 days, while for Ptp4E-RNAi HMS05000 it was 64 compared to 
D42-Gal4; UAS-lacZ, which was 66 days. As is shown in Table 19, the 95% confidence 
interval was 0.03410 – 0.04619 for RNAiHMS01838 in comparison to 0.03699 – 0.04897 
for the control group. 
The inhibition of Ptp4E using the neuron-specific transgene DDC-Gal4 led to a 
significant decrease in lifespan and climbing ability (Figure 24 & 25). The median 
lifespan for flies with the inhibition of Ptp4E-RNAiHMS01838 and Ptp4E-RNAi HMS05000 
with transgenic line DDC-Gal4 was 58 and 56, respectively, which is shorter than the 
control UAS-lacZ whose median lifespan was 72 (Table 20). The changes in climbing 
ability were also significant as the 95% confidence interval was 0.02234 – 0.03361 and 
0.05021 – 0.07713 for Ptp4E-RNAiHMS01838 and Ptp4E-RNAi HMS05000, which was 
compared to 0.04563 – 0.05455 for UAS-lacZ (Table 21). 
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Consistent with the above results for D42-Gal4 and DDC-Gal4 drivers, the 
inhibition of Ptp4E-RNAiHMS01838 with the dopaminergic neuron-specific TH-Gal4 
transgene resulted in the most significant decrease in longevity and climbing ability 
(Figure 26 & 27). The reduction for the other inhibition line of Ptp4E was also 
substantial. The median survival decreased from 72 in TH-Gal4; UAS-lacZ to 54 and 62 
in Ptp4E-RNAiHMS01838 and Ptp4E-RNAi HMS05000, respectively (Table 22). Based on 
Figure 27, Ptp4E-RNAiHMS01838 flies significant change, in which the 95% confidence 
interval was 0.03115 – 0.04695 in comparison to the control group with 0.04104 – 
0.05848 (Table 23). A summary of ageing and climbing analyses is provided in Table 
24 which suggests that all results except for one were significantly important. 
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Figure 22: Inhibition of Ptp4E using a motor neuron specific transgenic line (D42-
Gal4) causes a significant decrease in longevity. Two different inhibition lines were 
used and both were significant compared to the control D42-Gal4; UAS-lacZ. Longevity 
is shown by percent survival. Significance is p< 0.05 and error bars shows the standard 
error of the mean. 
 
 
 
 
Table 18. Comparison of the longevity of flies for the inhibition of Ptp4E in motor 
neurons by Mantel-Cox Log-rank statistics. Chi-square values and p-values were 
calculated using UAS-lacZ controls. 
 
Genotype Number 
of flies 
Median 
Survival 
(days) 
Chi – 
square 
value  
P-value  Significa
nt 
D42-Gal4; UAS-lacZ 306 66 N/A N/A N/A 
D42-Gal4; UAS-
Ptp4E-RNAiHMS01838 
293 54 1.749 <0.0001 Yes 
D42-Gal4; UAS-
Ptp4E-RNAi HMS05000 
338 64 31.82 <0.0001 Yes 
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Figure 23: Inhibition of Ptp4E using a motor neuron specific transgenic line (D42-
Gal4) causes a significant decrease in flies climbing ability over time. Two different 
inhibition lines were used. Both were significant compared to the control D42-Gal4; 
UAS-lacZ. Data were analyzed by a non-linear curve fit with 95% confidence intervals 
to determine significance. Error bars represent standard error of the mean. 
 
 
 
Table 19. Comparison of the climbing ability of flies for the inhibition of Ptp4E in 
motor neurons by using a non-linear regression curve for each inhibition line. 
 
Genotype 95% 
Confidence 
Intervals 
R2 P-value  Significant 
D42-Gal4; UAS-lacZ 0.03699 – 
0.04897 
0.8735 N/A N/A 
D42-Gal4; UAS-Ptp4E-
RNAiHMS01838 
0.03410 – 
0.04619 
0.8930 <0.0001 Yes 
D42-Gal4; UAS-Ptp4E-
RNAi HMS05000 
0.02919 – 
0.04020 
0.8536 <0.0001 Yes 
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Figure 24: Inhibition of Ptp4E using a neuron-specific transgenic line (DDC-Gal4) 
causes a significant decrease in longevity. Two different inhibition lines were used 
and both were significant compared to control DDC-Gal4; UAS-lacZ. Longevity is 
shown by percent survival. Significance is p< 0.05 and error bars shows the standard 
error of the mean. 
 
 
 
 
Table 20. Comparison of the longevity of flies for the inhibition of Ptp4E in neurons 
by Mantel-Cox Log-rank statistics. Chi-square values and p-values were calculated 
using UAS-lacZ controls. 
 
Genotype Number 
of flies 
Median 
Survival 
(days) 
Chi – 
square 
value  
P-value  Significant 
DDC-Gal4; UAS-
lacZ 
299 72 N/A N/A N/A 
DDC-Gal4; UAS-
Ptp4E-RNAiHMS01838 
366 58 302.6 <0.0001 Yes 
DDC-Gal4; UAS-
Ptp4E-RNAi HMS05000 
386 56 31.82 <0.0001 Yes 
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Figure 25: Inhibition of Ptp4E using a neuron-specific transgenic line (DDC-Gal4) 
causes a significant decrease in flies climbing ability over time. Two different 
inhibition lines were used. Both were significant compared to the control DDC-Gal4; 
UAS-lacZ. Data were analyzed by a non-linear curve fit with 95% confidence intervals 
to determine significance. Error bars represent standard error of the mean. 
 
 
 
 
Table 21. Comparison of the climbing ability of flies for the inhibition of Ptp4E in 
neurons by using a non-linear regression curve for each inhibition line. 
 
Genotype 95% 
Confidence 
Intervals 
R2 P-value  Significant 
DDC-Gal4; UAS-lacZ 0.04563 – 
0.05455 
0.9533 N/A N/A 
DDC-Gal4; UAS-Ptp4E-
RNAiHMS01838 
0.02234 – 
0.03361 
0.7874 <0.0001 Yes 
DDC-Gal4; UAS-Ptp4E-
RNAi HMS05000 
0.05021 – 
0.07713 
0.8203 <0.0001 Yes 
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Figure 26: Inhibition of Ptp4E using a dopaminergic neuron-specific transgenic line 
(TH-Gal4) causes a significant decrease in longevity. Two different inhibition lines 
were used and both were significant compared to the control TH-Gal4; UAS-lacZ. 
Longevity is shown by percent survival. Significance is p< 0.05 and error bars shows 
the standard error of the mean. 
 
 
 
 
 
Table 22. Comparison of the longevity of flies with inhibition of Ptp4E in motor 
neurons by Mantel-Cox Log-rank statistics. Chi-square values and p-values were 
calculated using UAS-lacZ control. 
   
Genotype Number 
of flies 
Median 
Survival 
(days) 
Chi – 
square 
value  
P-value  Significant 
TH-Gal4; UAS-lacZ 272 72 N/A N/A N/A 
TH-Gal4; UAS-
Ptp4E-RNAiHMS01838 
272 54 322.9 <0.0001 Yes 
TH-Gal4; UAS-
Ptp4E-RNAi HMS05000 
353 62 210.3 <0.0001 Yes 
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Figure 27: Inhibition of Ptp4E using a dopaminergic specific transgenic line (TH-
Gal4) causes a significant decrease in flies climbing ability over time. Two different 
inhibition lines were used. Both were significant compared to the control TH-Gal4; 
UAS-lacZ. Data were analyzed by a non-linear curve fit with 95% confidence intervals 
to determine significance. Error bars represent standard error of the mean. 
 
 
 
 
Table 23. Comparison of the climbing ability of flies with inhibition of Ptp4E in 
dopaminergic neurons by using a non-linear regression curve for each inhibition 
line. 
 
Genotype 95% 
Confidence 
Intervals 
R2 P-value  Significant 
TH-Gal4; UAS-lacZ 0.04104 – 
0.05848 
0.8594 N/A N/A 
TH-Gal4; UAS-Ptp4E-
RNAiHMS01838 
0.03115 – 
0.04695 
0.8185 <0.0001 Yes 
TH-Gal4; UAS-Ptp4E-
RNAi HMS05000 
0.03109 – 
0.03732 
0.9469 <0.0001 Yes 
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Table 24. A comparison summary of ageing and climbing analyses. Ptp10D and 
Ptp4E responder lines were crossed to D42-Gal4, DDC-Gal4, and TH-Gal4 transgenic 
lines. 
 
Responder lines Transgenic lines 
Inhibition D42 DDC TH 
Ageing Climbing Ageing Climbing Ageing Climbing 
UAS-Ptp10D-
RNAikk101775 
- ↓ ↓ ↓ ↓ ↓ 
UAS-Ptp10D-RNAi v8010 ↓ ↓ ↓ ↓ ↓ ↓ 
UAS-Ptp10D-RNAi 
HMS01917 
↓ ↓ ↓ ↓ ↓ ↓ 
UAS-Ptp10D-RNAi v1104 ↓ ↓ ↓ ↓ ↓ ↓ 
            Overexpression  
UAS-Ptp10DEP1172 ↓ ↓ ↓ ↓ ↓ ↓ 
             Inhibition  
UAS-Ptp4E-
RNAiHMS01838 
↓ ↓ ↓ ↓ ↓ ↓ 
UAS-Ptp4E-              
RNAi HMS05000 
↓ ↓ ↓ ↓ ↓ ↓ 
 
↓ is significant decrease and – is no significant change. 
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Discussion 
 
Parkinson Disease (PD) is a movement disorder that is considered to be among 
the most widely-occurring neurodegenerative diseases. The risk of having this disease 
increases with age, as 1 to 2% of the human population over the age of 65 years suffers 
from PD and this proportion increases with advanced age (Schapira, 1995). Commonly, 
it is known that resting tremors, rigidity, bradykinesia, and postural instability are the 
main motor symptoms of PD. Neuronal dysfunction or loss in the substantia nigra of 
the midbrain, to cause dopamine deficiency in the striatum, and intracellular aggregation 
of α-synuclein are the most noted neuropathological hallmarks of Parkinson Disease 
(Trinh et al., 2014). Multiple signal transduction pathways and sub-cellular mechanisms 
are involved in the underlying molecular pathogenesis of the disease: α-synuclein 
proteostasis, mitochondrial function, oxidative stress, calcium homeostasis, axonal 
transport, and neuroinflammation (Poewe et al., 2017). Understanding the functions of 
genes that have been found to lead to hereditary forms of PD can reveal the involvement 
of newly implicated cellular pathways and provide great insights into the disease 
etiology and reveal new cellular pathways. 
Growing knowledge of the genetic basis of some forms of PD has led to the 
identification of a number of genetic loci that cause familial PD or increase the risk for 
PD. PTPRH, via its Drosophila homologues, is the gene of interest selected to be the 
focus of this study due to its potential role in signalling to the mitochondria. Moreover, 
it has been found that inhibition of PTPRH in neuroblastoma cell lines as an in vitro 
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model leads to changes in mitochondrial morphology (Jansen et al., 2017). Potential 
PTPRH homologues in D. melanogaster have not been extensively studied in 
Drosophila models of PD. Two potential homologues have been identified in D. 
melanogaster (Jansen et al., 2017). Ptp10D and Ptp4E, two homologues of PTPRH, are 
the result of gene duplication. Partial functional redundancy of these two genes, 
especially in the nervous system, encouraged my research group to study the 
consequences of altered expression of these genes while exploiting the D. melanogaster 
organism model. To assess the effects of Ptp10D and Ptp4E on cell growth, cell death, 
longevity, and climbing ability, they were ectopically inhibited and overexpressed in D. 
melanogaster by using the Gal4/UAS system. 
 
Drosophila Ptp10D and Ptp4E are conserved across vertebrates and invertebrates 
The similarities between the potential homologues of PTPRH in vertebrates and 
invertebrates were determined by performing bioinformatics analysis. Alignment of the 
protein sequence of Homo sapiens PTPRH and D. melanogaster Ptp10D and Ptp4E 
shows that the PTPRH protein should share functional similarities with the products of 
the Drosophila homologues with a number of conserved domains present in these 
proteins (Figure 3 & 4). Fibronectin type III (FN3) repeats and the proteins tyrosine 
phosphatase (PTP) domain are conserved in Ptp10D and Ptp4E in Drosophila and 
PTPRH in humans. Although the PTP region is highly conserved, the placement of FN3 
domains may vary between proteins as do the differences in number of amino acid 
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residues in these proteins as human PTPRH is much smaller than either Drosophila 
Ptp10D or Ptp4E. 
Ptp10D, as the longer of the two Drosophila proteins contains nine FN3 
domains, while Ptp4E has eight and PTPRH has six. It is interesting to note that in 
addition to the PTP domain, four domains amongst six FN3 domains in PTPRH are well 
conserved in these three proteins. Of the remaining FN3 domains, one is conserved 
between PTPRH and Ptp10D, and another one is maintained between PTPRH and 
Ptp4E. In D. melanogaster, the Ptp10D and Ptp4E proteins share seven conserved FN3 
domains and one PTP domain. Clearly, the presence of conserved domains in human 
PTPRH and D. melanogaster Ptp10D and Ptp4E suggests that these proteins have a 
shared ancestor as well as comparable functions in the two species. While the number 
of FN3 repeats in vertebrates and PTPRH varies from six to eight (Figure 3 & 4), the 
range is seven to 12 among invertebrates (Figure 5). The comparison of Ptp10D and 
Ptp4E protein structures and sequences shows that they are 54% identical along the 
whole length of the protein and thus are very similar in function (Chicote, DeSalle, & 
García-España, 2017). There is only one copy of Ptp4E/Ptp10D in non-drosophilid 
species, which is more similar to Ptp10D (Matozaki et al., 2010). This provide further 
evidence that Ptp10D is the ancestral gene. Therefore, the Ptp10D sequence has been 
used in the multiple alignment for vertebrates and invertebrates (Figure 5). The multiple 
alignment indicates that, as mentioned before, PTP, which acts as a negative regulator 
for integrin-mediated signalling, is a highly conserved motif among vertebrates and 
invertebrates and might be associated with the inhibition of cell growth and motility. 
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Effects of RNAi-induced knockdown of Ptp10D in D. melanogaster 
The compound eye structure provides a valuable model system for studying 
neural tissue-related diseases for two main reasons: first, key signalling pathways that 
control basic developmental processes are conserved between humans and flies, and 
second, its unique structure allows any changes due to defects in neurodevelopment to 
be quantified. The D. melanogaster compound eye is made of 700 to 800 subunits called 
ommatidia and is a complex comprised largely of neural tissue (Frankfort & Mardon, 
2002). Thus, the presence of more than 6000 neurons in each eye makes the 
measurement of neurodevelopmental defects feasible even in cases in which only slight 
abnormalities are apparent. 
In a recent study, the inhibition of Ptp10D along with the co-expression of α-
synuclein was shown to enhance retinal degeneration, whereas the mutant allele in α-
synuclein null flies through Rhodopsin1-Gal4 does not cause significant α-synuclein 
toxicity (Jansen et al., 2017). In this experiment, I inhibited Ptp10D directly in the eye 
of D. melanogaster through eye-specific expression, utilizing the GMR-Gal4 transgenic 
line. The results demonstrate a decrease in both the number of ommatidia and 
interommatidial bristles. It should be noted that the reduced ommatidia number is slight 
but significant, while the decline in bristle number is relatively substantial (Table 3 & 
4). In addition to the three RNAi lines used in Jansen et al.’s study, I experimented with 
the Ptp10D-RNAiHMS01917 transgene which produced the most significant reduction in 
bristle number (Figure 10). Despite the uncertainty about the underlying reasons for this 
reduction, the decrease in the ommatidia and bristle numbers may be due to a reduction 
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in cell death or a decrease in cell growth (Brachmann & Cagan, 2003). Since there is a 
possibility for Ptp10D, being a subset of RPTP, to act as a cytoplasmic modulator in cell 
growth pathways, it may be inferred that the reduction in Ptp10D may lead to the 
disruption of cell growth pathways and therefore a reduction in ommatidia and 
interommatidial bristle number. 
Since a shorter lifespan is one of the characteristics of PD-associated phenotypes, 
longevity assays were carried out to recognize the impact of Ptp10D inhibition on the 
lifespans of critical class Drosophila. Four distinct inhibition lines were crossed to three 
directed expression Gal4-bearing transgenic lines, each of which had a specific profile 
of tissue of expression. Three out of four inhibition transgenes resulted in a significant 
decrease in lifespan when guided by the motor neuron-specific transgene D42-Gal4 
(Figure 11). Based on statistical comparison, D42-Gal4; UAS-Ptp10D-RNAiv1104 
produced the most significant reduction in which the number of median survival days 
decreases by 16 (see Table 6). Correspondingly, this transgene resulted in the largest 
decrease of all inhibition transgenes directed by the dopaminergic neuron-specific 
transgene TH-Gal4 (Table 10). It should be added that all the lines had a significant 
decrease in lifespan, but the decrease was the largest for Ptp10D-RNAi v1104 with a 
median lifespan of 14 days. The experiment was repeated with a neuron-specific 
transgene DDC-Gal4, which caused a decrease in all used inhibition lines. The most 
significant reduction in longevity was 22 days, in DDC-Gal4; UAS-Ptp10D-RNAi 
HMS01917, critical class males and the second most significant decrease was 18 days for 
the DDC-Gal4; Ptp10D-RNAi v1104 flies (Table 8). No other studies have been done to 
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analyze longevity and climbing ability through the manipulation of Ptp10D and Ptp4E. 
An apoptotic death of DA neurons, may lead to a decrease in cell survival (Lev, 
Melamed, & Offen, 2003) and consequently a shorter lifespan in transgenic flies in 
which Ptp10D is inhibited. Moreover, the Ptp10D protein probably has roles in cell 
growth pathways, which means its inhibition may lead to a disruption in cell growth 
pathways and, subsequently, earlier cell death and a shorter life span.  
Based on the above results regarding the deleterious effects of the inhibition of 
Ptp10D upon compound eye morphology and longevity, it was hypothesised that loss of 
Ptp10D activity may have adverse effects on climbing ability throughout the life of the 
flies. Moreover, the climbing assays are of great importance due to the nature of 
Parkinson Disease, which is linked with diminished locomotor ability during life. 
Therefore, locomotor analyses were conducted to examine the climbing ability of 
Drosophila over time. As expected, there is a noticeable decrease in the climbing ability 
of flies with the inhibition of Ptp10D when crossed with D42-Gal4, DDC-Gal4, and 
TH-Gal4 transgenic lines. Experiments on four inhibition lines with these different 
drivers have produced consistent results in which the UAS-Ptp10D-RNAiHMS01917 
inhibition line had the most significant decrease in climbing ability (Table 7, 9, and 11).  
This is the first time the effect of Ptp10D manipulation on the climbing ability 
of D. melanogaster has been studied, so the precise role of this protein in pathways 
related to climbing ability is unclear. However, there is evidence that supports the role 
of Ptp10D in CNS development, as the expression of this gene is limited to the axons of 
CNS in late embryos in flies (Yang, Seow, Bahri, Oon, & Chia, 1991). Furthermore, a 
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recent study showed that Ptp10D has a role in motor axon guidance (Oliva & Hassan, 
2017). The inhibition of this gene activity may strengthen the production of the LOF 
phenotype in motor axon guidance, which is crucial in neural development. The 
deleterious effects of Ptp10D inhibition on neurons and then the longevity and climbing 
ability suggest that the LOF of Ptp10D produces PD-like phenotypes. 
 
Effects of the overexpression of Ptp10D in D. melanogaster 
The overexpression of Ptp10D under the control of the eye-specific transgene, 
GMR-Gal4, has led to a significant reduction in the number of ommatidia and 
interommatidial bristles in the compound eye of D. melanogaster. Through biometric 
analysis, it has been shown that the decrease in bristle number compared to the control 
line is larger than the ommatidia reduction. Up to this point, there has been no previous 
research on the effects of the overexpression of Ptp10D in the eye of Drosophila. The 
observed decrease in the number of ommatidia and bristles suggests a significant 
reduction in cell number during eye development. A reduction of cell number can be 
due to either increased cell death or decreased cell growth (Kramer et al., 2003). From 
this, it may be inferred that the overexpression of Ptp10D might cause the inhibition of 
cell proliferation required for normal eye development. 
In my experiment, the overexpression of Ptp10D influences the longevity of D. 
melanogaster. When the overexpression transgene UAS-Ptp10DEP1172 was directed by 
the motor neuron-specific transgene (D42-Gal4), dopaminergic neuron-specific 
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transgene (TH-Gal4), and neuron-specific transgene (DDC-Gal4), a fairly consistent 
phenotype was achieved. All the critical classes derived from specifically designed 
crosses have given rise to a significant reduction in longevity. To be specific, the median 
survival of critical class flies directed by D42-Gal4, TH-Gal4, and DDC-Gal4 was 
shown to decrease by 12, 18, and 26 days, respectively. As was the case with the results 
of the inhibition of Ptp10D through longevity assays, the most significant reduction 
occurred when the DDC-Gal4 transgenic line was used (Table 14). Although a similar 
experiment has not been done on the overexpression of Ptp10D to compare the results, 
one study has shown that PTPRH overexpression led to apoptotic cell death in the 
fibroblast cell line, which is used as an in vitro PD model, through inhibiting the survival 
signalling pathways and activating the cellular pro-apoptotic pathways (Takada et al., 
2002). There is a strong probability that PTPRH has a key role in cell proliferation, 
survival, and cell apoptosis. As a consequence of Ptp10D being a potential homologue 
of PTPRH in D. melanogaster, it can be speculated that the overexpression of Ptp10D 
may increase apoptosis and/or decrease cell survival and therefore shorten the lifespan. 
The potential role of Ptp10D in cell survival encouraged the study of the 
potential effects of Ptp10D overexpression upon one of the most important neurological 
characteristics of PD, diminishment of locomotor ability over time. This study 
demonstrates that the overexpression of Ptp10D leads to a significant reduction in the 
climbing ability of critical class flies during the life of ageing flies. Similar to previous 
experiments, the overexpression line was crossed to three different tissue-specific 
transgenic lines to produce critical class males. The overexpression of Ptp10D, either in 
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motor neurons, dopaminergic neurons or a subset of neurons including the serotonergic 
and dopaminergic neurons results in lower climbing ability compared to the control 
group. Based upon the previous discussion, it seems that Ptp10D may have a crucial role 
in cell growth and survival and is essential for intact neural development. However, an 
optimal amount of gene activity is required for maintained locomotor activity as either 
too high or too low level of activity of Ptp10D has the demonstrated deleterious effects. 
 
Effects of Ptp4E inhibition in D. melanogaster 
The other possible homologue of PTPRH, Ptp4E, was inhibited specifically in 
the eye of Drosophila to determine if loss of function could lead to PD-like phenotypes. 
Two distinct RNAi transgenic lines were employed, and each led to deleterious effects 
upon the morphology of the Drosophila eye. Both methods of inhibition revealed a 
significant decrease in the number of ommatidia and bristles. In accordance with other 
results, the changes in bristle number were extreme and significant. Results similar to 
the inhibition of Ptp10D were to be expected due to the potential of functional 
redundancy between Ptp10D and Ptp4E. The assumption that Ptp4E may play a role in 
nervous system development, as it is expressed in the late embryo in a ubiquitous manner 
(Yang et al., 1991). However, a recent experiment produced a contrasting result (Jansen 
et al., 2017), as inhibition of Ptp4E in the developing eye through the directing 
Rhodobdin1-Gal4 transgene with two distinct inhibitory RNAi transgenes did not find 
significant retinal degeneration. 
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In further analysis, the effect of Ptp4E inhibition upon the longevity of critical 
class male flies was investigated. Two available Ptp4E-RNAi lines were crossed to 
different Gal4-bearing transgenic lines, including the motor neuron-specific transgene 
(D42-Gal4), dopaminergic neuron-specific transgene (TH-Gal4), and neuron-specific 
transgene (DDC-Gal4). The inhibition of Ptp4E results in a significant decrease in the 
lifespan of flies, as the median survival is decreased by 18 days in TH-Gal4; UAS-
Ptp4E-RNAiHMS01838critical class males, which lead to the most significant decrease in 
life span compared to the control group (Table 22). The Ptp4E-RNAiHMS01838 inhibition 
transgene caused a decline of 14 and 12 days in lifespan when directed by DDC-Gal4 
and D42-Gal4, respectively (Table 20 & 18). Due to the similarity between Ptp10D and 
Ptp4E in their function, it can be inferred that the inhibition of Ptp4E in flies may cause 
a decrease in cell survival to lead to a decrease in longevity. Consistent with the ageing 
results, Ptp4E-RNAiHMS01838 had the most significant decrease in climbing ability when 
directed by all three Gal4 transgenes used in the climbing assays. Since the climbing 
results for both Ptp4E-RNAi transgenes when they were under the direction of D42-
Gal4, DDC-Gal4, and TH-Gal4 were significant, it can be inferred that the inhibition of 
Ptp10D results in the production of PD-like phenotypes in D. melanogaster. 
 
Conclusion 
In this study, I have demonstrated that PTPRH has two homologues in D. 
melanogaster: Ptp10D and Ptp4E. Through bioinformatics analyses, it has been 
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suggested that these protein encoding genes, in Homo sapiens and Drosophila 
melanogaster, may have been functionally conserved due to the high level of sequence 
conservation, especially the presence of conserved domains including FN3 and PTP. To 
provide further justifications, the LOF and GOF of these two genes were studied through 
biometric, longevity, and climbing over lifetime assays. In addition, the inhibition of 
Ptp10D and Ptp4E through RNAi results in a significant reduction in ommatidia and 
bristle number, longevity, and climbing ability. The inhibition of each gene leads to a 
novel PD model. The overexpression of Ptp10D was analyzed through the same assays 
by one available overexpression line, and consistent results were obtained through the 
analyses of gene inhibition. Thus, in this experiment, the GOF of Ptp10D produced a 
PD-like phenotype as well. However, it would be worthwhile to further the study with 
additional overexpression lines of Ptp10D as well as Ptp4E. 
One of the most important objectives that may be accomplished in a follow up 
to the current study is the execution of an experiment with simultaneous knockdown and 
overexpression of both genes to eliminate any potential compensation due to redundancy 
in function of the orthologous gene and then compare the severity of phenotypes 
compared to those of this study. Moreover, due to the close association of PTPRH with 
a well-established PD gene FBXO7, the interaction of Ptp10D and/or Ptp4E with 
FBXO7 should be of great interest to study. Further studies to complement these genetic 
studies could be conducted, from a molecular and cellular point of view, to investigate 
the potential roles of Ptp10D and Ptp4E in cell growth and development. 
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